Sham-operated animals
policy
taxonomy




compliance ; treatment

Heart failure ; UK
CHF
air pollution ; heart failure
exercise ; cardiovascular system
Clinical

HF
EH
case-control study

diuretic ; heart failure
adverse events


reporting ; Cell ; Anand
doxorubicin
doctors ; blood transfusions
Heart failure ; bisphosphonates
cox proportional hazards
Caspase ; gene expression ; heart failure
right heart failure ; pulmonary hypertension

exercise ; cardiovascular health
surgery ; heart transplant recipients
hospital mortality
Renal artery stenosis
adverse events
HF ; pna
molecular mechanism



Liver disease
dXA
FM
devices ; heart failure


environment
mortality
heart failure ; Latin America
HF


breathing ; heart beat
trial
Heart rate


doctors
Nutrition ; heart failure
northwest united states
Cross-sectional

surgery
heart failure


Heart failure

clin
Sci
trans

trial
internal reliability ; cronbach
hypertension
genes

Hazard ratios ; cox regression
implanted monitoring devices
treatments
patient safety ; conditions
HR ; Ea ; afterload burden
deaths ; strokes
frailty ; heart failure

exercise ; heart failure
RAS ; atherosclerosis
MicroRNAs ; heart failure ; disease management
PSSS ; exercise training
heart failure ; preserved ejection fraction
Cardiology ; Bromodomain inhibition halts ; heart failure

heart failure ; cardiovascular death
cognitive function
co
vasopressin ; congestive heart failure
Mitral stenosis reversed ; medical ; heart failure
cardiac transplantation
medical conditions
impact of frailty ;HF

LV fibrosis ; ANS mice

dodson

CHF
hospital ; heart failure
intermediate frailty
competitive

autonomic balance
HFpEF
Jehovah ; Witness ; anemia
ST2
Heart failure ; cognitive impairment ; mortality
department of cardiology
follow-up duration
HF ; HF cases
exercise
markers of hemostasis
extracorporeal
Heart failure ; disease
HF ; MI

remote ischemic conditioning ; heart failure
Heart rate variability ; cardiac patients
cardiovascular disease
arrhythmia-related costs ; expenditures

pde2 ; HF
sts HM
physician ; hospital
Medication regimen ; sst2
Heart failure ; public health
postoperative normalization ; albumin level
follow-up

residual confounding
HF
hospital
mechanism ; ET ; CHF
eRK ; molecular scaffolds ; heart pathology
spironolactone ; systolic heart failure
cox proportional hazards models
Heart failure ;HF ; society
Epidemiology ; chronic heart failure ; bisoprolol
functional MS ; degenerative MR

VET ; aortic pressure curve
Cardiac symptoms ; children ; congenital lesions
Devices ; cornerstone of heart failure ;HF ; therapy
Trastuzumab-related cardiotoxicity ; breast cancer
physician continuity ; outcomes
readmission metric
Tolvaptan ; vasopressin ; receptor antagonist
metric ; readmission metrics

propensity

black
etiology ; MR ; MS
Cardiac amyloidosis
ejection fraction ; sex ; bNP
HFpEF
therapy ; beta blockade

Robot-assisted training ; heart failure

Chronic HF

Pigs ; antiarrhythmic medication
Heart rate ; arterial pressure
hgb level ; baseline ; HRQoL
ejection fraction outcomes
mortality
cardiac ; inflammatory biomarkers
HF ; cardiovascular hospitalization
CHF ; intubated
Surgical tactics ; hypothermic circulatory arrest
biomarkers ; chronic heart failure
heart failure ; emergency department
collected ; systolic dysfunction
HF
enrollment ; North America
acute heart failure trials

therapy
AHA ; ESC
cps
circulation
MS ; surgery
toxicity ; systemic blood pressure
heart failure
stand-alone diagnostic devices ;HF
end stage heart failure
clinician expertise ; HF


postoperatively ; multiorgan failure ; sepsis
Nordic walking ; heart failure
psychometric testing ; self-Care of Heart Failure index
baseline ; heart failure
acute kidney injury
cox proportional hazards models
endothelial function ; flow-mediated dilatation
heart failure ; cox proportional hazard
MS ; surgery ; echocardiography
Pharmacological ; acute heart failure

abnormal cardiac t2

heart failure
healthcare
biomarkers
main oUTCOME ; TUg test
trials


drug ; japan

VO2max
exercise
Coronary angiography
dialysis ; device implantation
off-pump ; sternal sparing ; HeartMate II exchange
Hemodynamic phenotype ; Fontan
ESRD
Survival projections ; Seattle Heart Failure model
factors ; survival
HR ;HF
Heart failure ; left ventricular ejection fraction
AI
acute heart failure

Treatment algorithms ; post-LVAD AI
nursing terminologies ; nursing
exercise training
anemia ; heart disease

QRs duration
hospitals
Rhythm- and rate-control

public reporting
sinus rhythm ; AF
septal ; filling pressures
telehealth ; medicare

deficit index ; deficits
physicians ; quintiles ;HF
heart failure ; cardiac rehabilitation
Race ; spironolactone ; heart failure
Myocardial infarction ; elicited ; Wistar rats

hawt ; chromatin hyperacetylation
mortality
gls ; cv events ; AF
ms ; surgery

medication ; resting hemodynamics

pathophysiological origin
systolic HF
postsystolic function
lVAD implantation
Readmission ; hospital ; heart failure
income ; expenditure ; health per capita

aac ; cardiac hypertrophy
physical ; heart failure
skeletal muscle abnormalities ; exercise capacity ; Fontan circulation
progressive disease ; lead ; hypertension ; kidney failure
chronic kidney disease ;CKd
longitudinal change
anaerobic threshold ; heart failure
Mitral regurgitation ; HF
CHF ; unilateral renal DNx ; cardiac autonomic balance
renin-angioten-aldosterone system inhibitors ; heart failure
abnormal HR variability ; cardiac death
inflammation ; metabolism ; heart disease
Heart block ; induced ; pulmonary artery snared ; biVP
congenital heart lesions
ms
AF ; echocardiographic examination
Bioinformatic ; genes ; heart failure
cardiovascular events
diuretic ; outcomes ;HF
CAD ; systolic HF
PVf ; recovery ; PB
Nurses ; patients
diabetes ;EO-cFUs
blacks ; peak VO2 ; baseline
odds ratios ; accounting ; hospital
change ; lVET ; follow-up measurement
nitroxyl ; hno ; acute treatment of heart failure
physician ; death ; urgent readmission ; discharge ; heart failure
hFrEF ; HFpEF
care packages
hospital-to-Home ; readmission reduction program ; congestive heart failure
economic savings ; accounting ; cost
HF
cRT ; dialysis-dependent patients
MS ;HF ; surgical indication ; MS
compliance
ICU
Cardiac function ; pressure-volume conductance ; catheter system
care ; RM
beta-blockers
CHF
sst2 ; BB therapy
evidence ;idiopathic dilated cardiomyopathy
Hypoalbuminemia ; heart failure
hypertensive LV dysfunction ; MR ; MS
cd HF ; etiologies
angiotensin receptor neprilysin inhibitor ; heart failure
western blot ; immunohistochemistry ; electron microscopy
diastolic dysfunction ; peripheral artery disease
unfolded protein response ; regulates cardiac sodium current ; systolic ; heart failure
ischemic cardiomyopathy ; mortality
exercise intolerance ; chronic heart failure
deficit index ; biological ; mortality
exercise training ;ET ; endothelial function
cv ; death ; non-fatal stroke ; hospitalisation ; heart failure
AVd ; VVD ; free wall RS
Fat ; cachexia ; right ventricle ; heart failure
atrial fibrillation ;AF ; heart failure
ect ; advanced heart failure therapy
heart transplantation ; left ventricular assist device
coronary disease ; heart failure
dialysis
right ventricular function ; body composition ; advanced heart failure
baseline ; eCGs ; electrocardiographers
left ventricular assist device ; right ventricular support
incidence ; ESRD ; outpatients ; HF
Wilcoxon ; signed-rank tests
subclinical atherosclerosis ; general linear models
connected elevated resistin levels ; heart failure
ff ; FM ; body weight ; CC
Renal artery stenosis ;RAS ; peripheral arterial disease
neurological ; cardiovascular
signalling pathways ; maladaptive cardiac remodelling
proteome ; HDl particles ; shotgun ;LC-MS
heart rate variation
social ; exercise ; exercise
rehospitalization
Cardiac cachexia ;cc ; body composition
MS ; surgery ; mVA
proteins ; TAC
Mediterranean ; DASh ; diet scores
heart failure ; nurse
Frailty ; HF
southeastern Minnesota ; HF
bundle branch block ; electrical activation sequence
hHF ; dp-4 inhibitors ; drugs
AF ; precipitating factor ; hff
heart transplant ; ECCT
cRF
death ; hospitalization ; heart failure clinic
Cardiac-resynchronization therapy ; heart failure
medications ; heart failure
miRNAs ; cardiac pathogenesis
heart failure care
bt ; DT
mortality rate
coronary heart disease ; stroke ; heart failure
MLHF
septal defects ; surgical
mortality ; iCD-HF
incident ; HF
treatment ; hypotension
clinical ; mortality
Î²-blocker ;BB ; sST2
medication lists
recovery
extubated ; blood loss ; transfusion
exchange malfunctioning HeartMate ; lVADs
Heart failure ;HF ; cardiovascular hospitalization
ST2 ; plasma samples
veGF inhibition ; b ; cardiac function
biomarkers ; treatment ; HF
trastuzumab-related CHF
aerobic exercise
hospitals

transplants
patient safety
Peak VO2
hospitals
pharmaceutically
bromodomain proteins
condition ; economic
financials ; enrolled
preoperative hypoalbuminemia ; lVAD surgery
holosystolic murmur ; third heart sound
psoriasis ; atherosclerosis ; incident cardiovascular events ; Rotterdam
Coronary artery disease ;CAD ; systolic heart failure ;HF
mortality ;HF ; hospital admissions ; transplant ; ventricular assist device
Heart failure ; rheumatoid arthritis ; tNF antagonist
HF ; haemodynamic ; neuronal stressors
lVAD implantation
renal dysfunction ; post-transplant morbidity
pre-HCT germline DNA
Heart failure disease ; medical
Renal DNx ; circulating plasma ; nef-inv rabbits
treatment
trastuzumab
np assessment ; ED
Cardiac hypertrophy ; energy metabolism
HF
blood work ; medication
s2 ; heart failure
Heart t2 ; heart failure ; arrhythmias
band of activated Caspase ; paced myocardium
heart failure ; health ; aging ; body composition
hf ; saxagliptin ; sitagliptin
HF
aCR ; CMS
HDl-bound malondialdehyde ; HDl-induced ; production
ED ; intubations ; congestive heart failure
derivation cohort ; CAD ; CAD


Survival ; hospital discharge
hospitals
anemia ; heart disease
heart failure ; medication
expression ; regulatory subunit ;RI ; HF
heart failure ; ejection fraction
cp ; guiding exercise rehabilitation ; CHF
nafat ; mir-25 ; transcription factor ; hand2 ; heart failure
Pediatric heart failure ;HF
eplerenone
renal denervation ; autonomic balance ; rabbits ; chronic heart failure
change ; readmissions ; follow-up visits ; heart failure ; readmission
resistin ; ejection fraction
right atrial myxoma ; pulmonary embolism ; right heart failure
Orthotopic heart transplantation ; ot ; end-stage heart failure
Myxomas ; right atrium ; pulmonary arterial vasculature
baseline ; ect ; cardiac transplant recipients
deficit index
Diet ; vegetables ; nuts ; whole grain intake ; mortality
evidence

iron
ED ; CHF
right ventricular contractil reserve ; pulmonary hypertension
Gastrointestinal bleeding ; ventricular assist devices ; cardiac nurse
Soluble ST2 ; ambulatory patients ; heart failure
baseline ; echocardiograms ; reverse remodeling
Titin hypophosphorylation ; myocardial DD
remote monitoring ; hospital discharge ; heart failure
bottleneck stent model ; chronic myocardial ischemia ; heart failure ; pigs
QT intervals ; SD ; QT intervals ;SDQT
LV ; filling pressure ; stable ; systolic HF
Medline ; EMBAse ; cinahl
RAS- ; Î²-blocker uptitration ; HFpEF
cps ; functional capacity ; peak VO2
pump failure ; driveline injury ; isolated pump replacement
ischemic ; inflammatory abdominal problems ; MT
EH ;HFpEF
Framingham Heart study ; HF ; EF
Nicorandil ; doxorubicin
evidence-based therapies ; fes
evidence ; aCP ; clinical practice
diuretics ; congestive symptoms ; heart failure ;HF
apoptosis ; canine model ; chronic heart failure induced ; tachycardia
lVAS ; bridge to transplantation ; destination therapy
Cardiac ; Mammalian ;Mena ; heart failure ; mice
east ; rhythm control therapy ; cardiovascular complications ; AF
radiological ;HF
exercise ; coronary artery disease ;CAD
NOc ; outcome ratings ; admission ; discharge
HRQol ; exercise training ; baseline ; hgb
skeletal muscle mass ; VO2
atrial fibrillation ; pacemaker
inpatient records ;HF
active treatment
cardiac resynchronization therapy ; dialysis-dependent patients ; heart failure
pneumonia ; conditions
diastolic failure ; cardiomyopathic restriction ; flow
compliance ; exercise ; injections
pump exchanges ; pump malfunctions ; pump thrombosis ; hemolysis events
emergency cardiac catheterization ; extubated ; intermediate care
psychosocial factors ; exercise training ; heart failure ;HF
medical ; heart failure ; Canadian Cardiovascular society
ees ; ventricular-arterial coupling ; SV
QRs
autonomic nervous system activity ; QTV
device implantation ; cRT
report model ; aRIC HF model

clinical change
degs ; osprey
therapy
world health organization ; HF ; LA
Medicare ; post-acute care transfer policy
patients ; cardiovascular
disease ; paediatric cardiac transplants
AF-free probability ; catheter ablation ; factors ; sinus rhythm
body mass index ; cRF ; treadmill exercise testing
myocardial tissue ; pKA
mortality predictors ; iCD-HF
t1 ; myocardial fibrosis

Medicare ; fee-for-service ; hospitalizations

white
exercise ; diet adherence

ethics Rounds

survival ; heart failure
ED ; CHF ; intubation rates
bisoprolol ; mortality
health Buddy program ; telehealth system ; care
muscle-wasting syndrome ; acquired heart failure ; Fontan
Frailty ; health outcomes
heart rate reduction ; ivabradine unloads ; left ventricle ; heart failure
rvpo ; biVP ; RS synchrony
anemia ; heart disease ; american college of Physicians
cardiovascular death ;HF ; exercise training ; btes
exercise training ; chronic heart failure ; high-density lipoprotein
Heart rate ; aortic blood flow ; doxorubicin

myocardial pde2 expression ; activity ; HF
resistin ; acute anthracycline-induced cardiotoxicity
acute autonomic nervous system modulation ; QTV ; HF
BAT ; sympathetic outflow ; parasympathetic activity
end-stage renal disease ; outpatients ; systolic heart failure
Neurohormonal abnormalities ; pathophysiology ; congestive heart failure ;CHf
echocardiographic predictors ; reverse remodeling ; cardiac resynchronization therapy
parasympatic neurotransmission ; acetylcholinesterase inhibition
renal DNx ; cardiac autonomic balance ; CHF ; sympathetic tone
Heart Failure ; pathophysiology ; medical Treatment guidelines
neurohormonal stimulation ; inflammation ; endothelial dysfunction
proof-of-principle cohort study
activity ; i-mib ; myocardial washout
right ventricle ;RV ; cardiac function ; medical
costs ; heart failure ;HF
radiological ;HF
inhospital mortality ; bNP
cardiopulmonary exercise variables ; heart failure
RV dysfunction ; weight loss ; fat ;lean body mass ratio
chromatin subproteome ; mouse heart
HR reduction ; beta blockers ; exercise capacity ; hFrEF
inhibition of protein kinase ; soluble guanylate cyclase ; contractile
t test ; cs
cps ; functional capacity ; heart failure ;HF
morbidity ; mortality
Mortality ; aCS
PSs ; social ; btes ; exercise
ctnt ; NT-probNP ; HF
Jehovah ; Witness ; sickle cell disease ; anemia
miRNAs ; heart failure
physician continuity ; conditions ; hospital discharge
l-type ca2 ; currents ; Rad ; congestive heart failure
congestive heart failure ;CHf
health Buddy program ; ED
mri scanner ; baseline ; heart failure
defense mechanism ; cardiac stress ; Î²-AR drive
pulmonary artery ; right pulmonary artery
dobutamine ; furosemide dose ; oxygen flow
LVEF ; long-term mortality
Mediterranean ; DASh ; diet scores ; mortality ; heart failure ; women ; health Initiative
cps ; outcomes ; diabetes
anthracycline-treated breast cancer ; cardiotoxicity
death ; transplantation ; circulatory assist device
outcome change scores ; hospitalized older adults ; heart failure
therapeutic ; devices ; fluid overload
exercise
transcatheter ; surgery
Human resistin ; chemotherapy-induced heart failure ; breast cancer
insurance status
black race ; mortality
chelation regimes ; heart iron
Time up & go test ; chronic organ failure
death ; heart failure
baseline ; ST2 ;interquartile range
pressure ulcers ; surgical patients
HF ; valve plasty ; ms ; mVA
PD ; refractory ; end-stage congestive heart failure ;CHf
NYHA
beta blockers ; mortality ; heart failure
MT ; abdominal problems
follow-up
mortality
futility ; monitoring board
diagnostic procedures
stress doppler echocardiography ; pulmonary hypertension
ejection fraction ; cardiac resynchronization therapy ; mild heart failure
co correlated ; septal wall ; AVd ; free wall ; VVD
LV ; strain rate ; echocardiography ; baseline
changes ; circulating progenitor cells ; heart failure
etiologic ; acute RV failure ; left ventricular dysfunction
systolic ; diastolic ; mitral leaflet ; organic lesion
myocardial diastolic dysfunction ;DD ; collagen deposition ; titin
left ventricular ejection time ; acute heart failure ; precapillary pulmonary hypertension
aortic valve insufficient ; left ventricular assist device implantation
biventricular pacing ; left heart twist ; strain ; porcine model ; right heart failure
cardiac nurses
closure
UM/VA ;VA-RT
heart failure
cost-effective ; health
Czech Republic
cardiac catheterization ; thrombotic obstruction ; right coronary artery
western blots ; monoclonal antibodies ; ser83 ; phosphorylation ; HF
hff ; dietary sodium restriction ; ventricular ; vascular stiffness
echocardiographic ; invasive hemodynamic
chronic heart failure ;CHf ; sympathetic tone ; autonomic imbalance
California ; office of statewide health planning and development Patient discharge
right atrium mass ; prolapse ; tricuspid valve ; stenotic physiology
preoperative serum albumin levels ; left ventricular assist device implantation
walk test ; mwt
nursing ; outcomes ; hospitalized older adults ;HF
CHF ; atrial explants ; c-Kit ; explants
herbal medicine ; dilated cardiomyopathy ; heart failure
implantable cardioverter-defibrillator deactivation

economic impact ; AF ; heart failure ; QuÃ©bec
cardiac Mena deletion ; cardiac dysfunction ; conduction abnormalities ; hypertrophy
mechanism ; prolonged electromechanical delay ; dyssynchronous heart failure
trastuzumab ; cardiac
bundle-branch block ;LBb ; non-LBb
Font failure ; systolic ventricular function ; liver disease
EH ; CH ; cardiac filling pressures
protein levels ; western blot ; DNA fragmentation ; TUNEL method ; autopsy
extracorporeal membrane oxygenation ; bridge to recovery ; infarction-related refractory right heart failure
apoptosis ; pacing-induced dilated cardiomyopathy
Heart failure ; society ; cardiovascular diseases
Magnetically Levitated Left Ventricular Assist system ; treatating Advanced HF
anticoagulation ; therapy ; underlying heart disease ; rate control
inotropic effect ; beta blockers ; heart failure
PAD ; ankle-brachial index
HR reduction ; ivabradine ; TAC
NT-probNP ; circulation ; HF
energy metabolism ; heart failure ; hypertrophied heart
cancers ; health-care budget
baseline ; mechanical cardiac support ; renal function
systolic function
ecmo group ; VAD ; ecmo+VAD groups
psoriasis ; smoked ; diastolic blood pressure ; body mass index
Treatment group effects ; HRQoL
ED ; hospitals ; New Jersey ; New York
cox models ; ST2
MS ; dynamic ; LV dilatation ; MS
transfusion thresholds ; mortality
TM ; sts
HF
Seattle Heart Failure model
MAD-cRT
neurological ; cardiovascular event-free rate
BETs ; mouse TAC model ; human HF
chemical instability ; cogeneration of nitrite ; vascular
aHF

HDl-induced NO production ; flow-mediated dilatation ; et
dopamine ; nesiritide strategy
cutoff level ; NT-probNP
human heart failure ; altered protein kinase ; subunit expression
cox regression ; cardiovascular events ; psoriasis
cp ; HF
Paco2 ; cerebral blood flow ; perfusion ; carotid bodies
functional MS ; medical treatment ; surgical
HF epidemiology ; health service provision ; HF ; LA
heart failure ;HF
renal dysfunction ; mechanical cardiac
Heart failure ;HF
ventricular assist devices ; device therapies
hemoglobin ; health outcomes
cf
clinic ; primary care clinicians
heart failure ; systolic heart failure
baseline ; rhythm-control ; rate-control
CF lVAD ; AI ; heart failure
anemia ; heart disease
left ventricular dilatation
serum factors ; coagulability
device
PB ; HF ; primary oscillations ; central pattern generator
icd

HF
computing readmissions ; hospital rankings ; pay-for-performance
echocardiography ; baseline ; shunt implantation
pro-adrenomedullin ;MR-proADm ; fm
New York Heart association ; walk test
ms ; ring annuloplasty ; ischemic MR ; LV
exercise intolerance ; heart failure
pathophysiology ; HF
ventricular assist device ; extracorporeal membrane oxygenation ; renal function ; pediatric heart failure
interleukin receptor family ; ST2 ; beta-blocker therapy ; chronic heart failure
bNP ; NT-probNP ; diagnostic ; biomarkers ; heart failure
Cardiorespiratory fitness ; body mass index ; heart failure mortality ; Cooper center Longitudinal study
vasopressin receptor antagonist ; tolvaptan ; Japanese heart failure
diet ; exercise
hospitals ; metric
acute HF ; outline
administration ; trastuzumab ; CHF

sudden cardiac death
biomarker-guided trials
hospital mortality
medical records
ejection fraction ;EF ; infarct ; collateral growth ; myocardial perfusion
Heart failure ;HF ; sympathetic activity ; parasympathetic control ; heart
physical activity ; cardiovascular risk factors ; obesity ; diabetes mellitus ; hypertension ; hyperlipidaemia
Circulating fragments ; N-terminal pro-B-type natriuretic peptides ; plasma ; heart failure
heart failure ;HF ; left ventricular ejection fraction ;HFpEF
atrial fibrillation ; congestive heart failure ; cost ; rhythm-control ; rate-control
HF ; cardiac murmurs ; blood pressure ; hg
ATP demand ; XO-mediated ROS ; mitochondrial respiration ; contractile function
b ; cardiac angiogenesis ; in vivo coronary perfusion ; cardiac fibrosis
instability ; heart failure ; prone ; ventricular tachycardia
TUg test ; COPd ; CHF ; cRF
signaling pathways ; pressure-overload-induced heart failure
Nursing ; social mandate ; accountable ; outcomes ; nursing care
HF ; VT ; beat-to-beat QT intervals
biventricular dysfunction ; isolated HeartMate II
procedure ; hemodynamically unstable ; cp
end-stage heart failure ; implantation ; long-term ventricular assist device
Pyridostigmine ; myocyte diameter ; collagen density ; left ventricle
isoproterenol ; cXL-1020 ; myocytes ; hearts
exercise intolerance ; chronic hff ;QOL
receptors ; adenylyl cyclase ; differential g-protein coupling
systolic HF ; unclear etiology ; coronary angiography
predictors of mortality ; implantable cardiac defibrillator
jugular venous pressure ; peripheral oedema
Heart failure ;HF ; condition
clinical prediction rule ; CAD ; systolic HF
pump-exchange technique ; redo sternotomy ; cardiopulmonary bypass
Surgical revascularization ; catheter-based revascularization
baseline ; hgb ; exercise training ; kccq
medical ;HF ; HF ; ms ; mVA
MS ; medical treatment ; HF ; MS ; dynamic ; medical
sonographic ; histological ; functional abnormalities ; gastrointestinal
evidence ; parasympathetic function ; HF evolution
exercise training ; ambulatory HF
mechanical cardiac support ; renal function ; end-stage heart failure
EH ; systolic blood pressure ; renal impairment ; hypertension
chronic myocardial ischemia ; heart failure
Morpholino-based knockdown ; nucleolin ; protein expression
hospital length of stay ; rehospitalization
HFpEF
rule ; CAD ; CAD
diabetes mellitus ; cardiovascular disease ; baseline
HF-related cachexia ; RV function ; body composition
prediction rule
ecmo group ; egFR ; egFR
exercise ; haemodynamic ; pulmonary ; peripheral abnormalities
general hospital ; cardiac specialty hospital ; south dakota
cognitive impairment ; mortality
aCS ; MT ; VAD
cvd ; psoriasis
energy substrate metabolism ; working hearts ; aac
evidence ;SCHfi
Rotterdam ; psoriasis ; cardiovascular outcomes
HR ; tNF antagonists ; nbDMARD
Spironolactone ; hyperkalemia ; acute kidney injury
hereditary ; congenital abnormalities ; heart ; nontraumatic death ; sport
Fontan circulation ; skeletal muscle mass ; metabolic abnormalities
evidence-based practices
cardiovascular conditions ;HF
isolated HeartMate II lVAD
albumin levels ; lVAD ; postoperative survival
mineralocortic receptor antagonists
right heart circulation ; right heart failure
early-onset ; MI ; late-onset ; MI ; HF
Fontan circulation ; sVR index ; cardiac index
isolated lVAD ; biventricular
health insurance ; health system ; u.s. Food and Drug administration
cutoff value ; NT-probNP testing ; ED ; acute heart failure
blacks ; hypertension ; diabetes ; ischemic etiology ; socioeconomic
bisphosphonate ; heart failure
cytoscape ; DAVID
Raf-MEK1/2-ERk1/2 ; signalling pathway
costs ; survival

clinical care
patient safety
HF-induced remodeling ; emd prolongation
mouse ; HF model ; transition ; compensated LV hypertrophy ; HF ; hh
heart failure ; preserved ejection fraction ; clinical doppler echocardiography
natriuretic peptide levels ; biomarkers
anticoagulants ; antiplatelet drugs ; heart failure ; atrial fibrillation
sympathetic ; parasympathetic activity ; HF
left ventricular longitudinal systolic strain ; cardiovascular events ; atrial fibrillation
heart transplantations ;LV assist device implantations ; heart failure admissions
functional mitral stenosis ; ring annuloplasty ; ischemic mitral regurgitation
Xanthine oxide inhibition ; left ventricular systolic ; diastolic function ; cardiac
bNP levels ; PAD ; bNP measurements ; HF
heart failure ;HF ; Heart Failure adherence and retention Trial ;HARt
HF ; preserved ejection fraction ;HFpEF ; hypertension
NYha ; quality-of-life score
myocardial infarction ; left anterior descending coronary artery occlusion
HFpEF ; breathlessness ; fatigue ; fluid retention
immunodetection ; NT-probNP ; antibodies
Nordic walking ; cardiac rehabilitation ; functional capacity ; heart failure
parasympathetic tone ; pyridostigmine ; ventricular dysfunction ; onset of heart failure
Î²-Blockade ; cardiac angiogenesis ; heart failure ; veGF
myocardial ischemic events ; cardiac resynchronization therapy
report ; aortic valve surgery ; post-LVAD AI
unloading of the heart ; isolated HR reduction ; systolic heart failure
spironolactone ; systolic heart failure
Heart failure ; medicine ; atheromatous coronary disease
Heart failure ;HF ; Latin America ;LA ; health service planning ; HF
rehospitalization ; medicare ; fee-for-service ; discharged
HF ; hospitalization ; cRT ;hazard ratio
palliative care ; disease
diagnostic test ;HFpEF ; medical ; physical
oxidative stress ; GTPase Rac1 ; activity ; hearts ; ANS
resistin ; circulating mediator of insulin resistance ; monocytes ; inflammatory stimuli
cardiovascular death ; urgent cardiac transplant
medications ; outpatients ; heart failure ; NCd PINnaCLE
beta-blockers ; cardiac sympathetic activity ; hemostasis ; heart failure
CHF ; emergency department ;ED ; intubated
mortality ;LCx ; LAD ; two-vessel disease model
RV dysfunction ; weight loss ; body composition ; HF
congestive heart failure
mitochondrial ; reversal of detrimental alterations ; sarcomeric
art failure ; Emergency department ;ED ; ED
degs ; non-ischemic ; ischemic heart failure
pp ; aCR ; CMS
gut ; inflammation ; heart failure ; heart failure
heart failure ; ejection fraction
Intravenous iron ; heart failure ; iron deficiency
robot-assisted gait therapy ; Lokomat ; heart failure
stress conditions ; maladaptive remodelling ; heart failure
trial
readmission rate


psoriasis ; systemic ;UV treatment
NT-probNP ; HF ; immunoprecipitation ; mass spectrometric
Chromatin-associated proteins ; chromatin structure ; DNA ; gene expression profile
diastolic dysfunction ; hFPEF
right ventricle overload leads ; stroke volume ; left ventricular ejection time ; lVET
Î²-Adrenergic receptor blockade ; hospitalizations ; heart failure ;HF
PD ; hospitalizations ; therapy ; HF
transoesophageal echocardiography ; shunts ; patent ; thrombosis ; migration
hand2 ; heart muscle ; pathological hypertrophy
physician ; follow-up ; discharge ; death ; readmission ; heart failure
dialysis ; echocardiographic outcomes
zf1 rats ; heart failure ; ejection fraction
ambulatory HF ; left ventricular ejection fraction
QT variability ; qt ; repolarization lability ; Qt ; sudden cardiac death
cross-talk ; heart ; adipose tissue ; cachectic heart failure ; body composition
arterial tonometry ; lVET ; precapillary PH ; heart failure
heart magnetic resonance imaging ; chelation choices ; compliance ; heart disease ; thalassaemia
PARADIGm-HF ; chronic heart failure ; Chronic heart failure ; cardiology
aIM ; implantable cardioverter-defibrillator deactivation
white rabbits ; renal DNx ; pacing-induced CHF
ET ; HDL function ; ET ; CHF-NYha-IIIb ; HDL function
catheter ablation ; antiarrhythmic drugs ; rhythm control therapy
lVET ; death ; ICU
exercise ; hemodynamic
Cardiac failure ; type 2 diabetes ; molecular mechanism ; diabetes ; heart failure
pulmonary hypertension ;PH ; heart failure
Beta-blocker dose ; resting HR
CHF ; therapeutic interruption ; activated neurohormonal systems
uptitration ; heart rate ; renal function ; spironolactone
microRNAs ;miRNAs ; pathogenesis ; heart failure
t1-mapping ; mri ; tidal respiration ; myocardial t1 ; swine ; heart failure
medical ; HF
miRNAs ; cardiac remodeling ; heart failure
cutoff ; e ;septal
cardiovascular disease ; dRS deciles
inappropriate therapy
hospital ; AMI ; mortality rates
proteins ; conservation ; acid
frailty ; heart failure ;HF
heart failure ; bisphosphonates
beta-blocker therapy
psoriasis ; cardiovascular disease ;CVd
pde2 ; cardiomyocytes ; norepinephrine-induced hypertrophic responses
readmissions
cardiovascular disease ; baseline
costs
technology
Rhythm control therapy
RAS-blocker uptitration ; hFrEF ; HFpEF
LV diastolic dysfunction ; filling pressures ; doppler echocardiography
Hemoglobin ; exercise training ; health status ; chronic heart failure ;HF-ACtion
cardiac dysfunction ; subcellular alterations ; metoprolol ; heart failure ; myocardial infarction
myocardial collagen ; collagen cross-linking ; titin isoforms ; phosphorylation
Cardiac magnetic resonance postcontrast ; heart failure ; ejection fraction
systems proteomics ; cardiac chromatin ; nucleolin ; regulator of growth ; cellular plasticity ; cardiomyocytes
cardiotoxicity ; doxorubicin ; anti-neoplastic agent ; cancers
heart failure ; left ventricular ;LV ; ejection fraction
Fontan ;SAF ; catheterization
natriuretic peptides
AlphaLISa ; immunoassays ; NT-probNP
HF ; rheumatoid arthritis ;RA
financial ; hospital rates ; HF ; CMS metric ; conditions
implantable cardioverter-defibrillator deactivation
sinus rhythm ; antiplatelet agents ; anticoagulants
death ; c-statistics ; biological phenotype
Î²-Blocker-induced enhancement of cardiac angiogenesis ; therapy ; cardiac function
physician ; index admission
expression ; Bax ; bcl-2 proteins ; dogs
GDMT ; control group ; GDMT ; BAT
heart failure ; CLnKA sNP
alendronate ; alendronate ; heart failure
transduction pathways ; signalling proteins
baseline ; HR
Plasma samples ; HF
regulation of feeding ; nutritional ; anti-inflammatory effects ; CHF
clinical diastolic dysfunction ; mortality
aCS ; oHT bridged ; transplant ; MT ; VAD
RAS- ; Î²-blocker dose
drugs ;HF ; ejection fraction ;HFrEF
Kansas City ; Cardiomyopathy Questionnaire ; heart failure ; ejection fraction
heart failure ; preserved ejection fraction ; hff
bn ; NT-probNP ; coronary artery disease ;CAD
functional mitral stenosis ;MS ; ring annuloplasty ; ischemic mitral regurgitation ;MR
heart failure-related hospitalization ; death ; left ventricular ejection fraction
hospitalizations ; refractory congestive heart failure ; peritoneal dialysis
heart failure ; elevated left atrial pressure ; hospital admission
lean zSF1 group ; obese ZSF1 groups ; hypertensive ; diabetic
tissue doppler imaging ; left ventricular filling pressure ; systolic heart failure
Heart failure ; preserved ejection fraction ;HFpEF ; cardiovascular morbidity
MT ; VAD groups ; aCS ; operations
LV ; diastolic dysfunction ; figure ; mechanism ; hff
Mammalian enabled ;Mena ; regulator ; cytoskeletal actin dynamics ; heart failure ;HF
Gastrointestinal bleeding ; ventricular assist devices
ARNI inhibitors ;angiotensin-receptor neprilysin inhibitors
fes ; preserved ejection fraction ;HFpEF
myxomas ; cardiac benign tumors ; right atrium
nicorandil ; cytotoxic effect ; doxorubicin ; Ehrlich carcinoma
ambulatory iCD patients ; predictor ; mortality
Heart failure ; preserved ejection fraction ; hff ; failure of cardiovascular reserve
Renal denervation ; dnx ; CHF
physician ; follow-up ; discharge ; physician continuity ; heart failure
hyperkalemia ; acute kidney injury ; spironolactone
myocardial pde2 ; intracellular antiadrenergic therapeutic strategy ; HF
carotid intima-media thickness ; psoriasis
coronary occlusion ; collateral growth ; stent occlusion
HF
exercise ; diet ; peak VO2 ;joint effect
spironolactone ; medications
RV dysfunction ; cardiac cachexia
ecg ; cRT
mechanical dyssynchrony ; QRs complex ; cRT
pharmacologic treatment ; clinical trials ; pharmacologic
ip ; heart failure ;HF ; death ; cRT-d
chronic heart failure ; Hungary
breast cancer ; trastuzumb-related CHF
remote monitoring ;RM ; heart failure
Process
NT-probNP
PVf ; PB cycle ; recovery period ; low BP
transfusions ; heart disease
exercise group
sst2 ; low-dose BB ; cardiovascular event rate
clinical variables ; ect
aerobic capacity ; left-hand grip strength ; body weight ; waist circumference ; anxiety
myocardial loss ; iRS1 ; iRS2 ; heart failure ; p38alpha MAPK ; insulin resistance
heart failure ; hypertensive heart disease ; angiotensin II infusion ; nephrectomy ; salt loading
shortened lVET ;ICU admission ; precapillary PH ; heart failure
Renal dysfunction ; mortality ; cardiovascular events ; postoperative months ; primary isolated caBG
baseline ; isoprenaline infusion ; SDQT ; hNorm ; HF
heart failure ; ejection fraction ; myocardial infarction
coronary artery disease ; systolic heart failure ; unclear etiology
ea ; arterial compliance ;TAC ; end-systolic elastance ; ees ; baseline
clinical trials ; aldosterone antagonist ; heart failure
Genetic susceptibility ; anthracycline-related congestive heart failure ; haematopoietic cell transplantation
cardiovascular risk factors ; diabetes mellitus ; atrial fibrillation ; coronary artery disease ; HFpEF
Renal dysfunction ; long-term mortality ; myocardial infarction ; coronary artery bypass grafting ;cab
biventricular support ; HeartMate ; lVAD ; centriMag RVAD ; mortality
angiogenes ; post-myocardial infarction heart ; progression ; heart failure
pde2 ; failing hearts ; desensitizes ; acute Î²-AR stimulation
surgery ; medical ;HF ; hypertension ; vasodilators ; diuretics
egFR ; diuretics ; uncontrolled hypertension ; ESRD
heart failure ; hospitalisation
Point-of-care systems ;NP levels ; ED ; outpatient settings ; acute heart failure
EO-cFUs ; mortality ;hazard ratio
trastuzumab ; CHF ; nontrastuzumab
anemic ; iron-deficient adult patients ; heart disease
HR reduction ; beta-blocker therapy
acute heart failure ; aHF ; heart failure ;HF
psoriasis ; disease ; atherosclerosis ; cardiovascular events ; psoriasis
HF remodeling ; emd ; dyssynchronous failing heart
Pyridostigmine ; vascular endothelial growth factor ; left ventricle ; myocardial angiogenesis
idiopathic dilated cardiomyopathy cohort
cardiac growth ; plasticity ; disease recapitulates ; developmental chromatin remodeling
CHF ; international classification of Diseases ; Ninth revision
MEDline ; EMBAse ; cochrane ; clinical trial registries ; technical advisors
egf ; VAD group ; ecmo ; VAD group ; ecmo
baseline ; ea ; TAC ; HR ; ees ; ivabradine
ERC ; pure epicatechin ; muscle function
Robot-assisted gait therapy ; LokomatÂ® system ; heart failure
baseline ; cRF ; HF mortality risk ; HF risk factors
RV dysfunction ; body mass index ; fat mass index ; cachexia
HF ;HF
myocardium ; expression ; pKA ; downstream signaling
care management ; content-driven telehealth technology ; health outcomes ; Medicare
hff
exercise ; health ; cardiac disease ; heart failure
HDl function ; CHF ; ET ; HDl-mediated vascular effects
HF ; risk factors ; fit ; HF mortality
physician adherence ;HF cPGs
lVAS
biomedical reasons ; nonprescribing
black race ;HF ; hospitalization ; cardiovascular mortality
dopamine ; nesiritide
Clinic
Shunt implants ; transseptal catheterisation ; transoesophageal echocardiographic ; general anaesthesia
isoelectric focusing ; RIÎ± ; ser77 ; ser83 ; vivo phosphorylation sites
baseline ; NT-probNP ; MR-proanp ; MR-proADm
tNF antagonists ; HF ; hospital admissions ; nbDMARDs ; RA
epidemiology ; myocardial infarction ;MI ; heart failure ;HF
Heart rate reduction ; exercise performance ; onset heart failure ; ejection fraction ; beta-blocker hypo-response
HeartMate II ; biventricular ; HeartMate II implantation
change ; ST-segment-elevation MIs ; Killip class ; conditions
bem-cRT ; multicenter Automatic Defibrillator Implantation ; Cardiac resynchronization Therapy ; nrt00180271)
admission ; serum levels ; brain natriuretic peptide ; bem ; creatinine ; natremia
RAS ; hypertension ; nephropathy ; congestive heart failure
MS ; valve plasty ; degenerative MR ; LV ; disease
elastic N2Bus segment ; pevk
end stage heart failure ; Heart failure ; public health ; europe ; north America
Nicorandil ameliorates mitochondrial dysfunction ; doxorubicin-induced heart failure ; mechanism of cardioprotection
HeartMate ; left ventricular assist system ; lVAS ; advanced heart failure
cXL-1020 ; hno ; inactive ; cXL-1051
arterial elastance ; ea ; pulsatile afterload ; heart ; pressure volume relation
pharmacologic ; acute HF ; adverse event rates ; chronic HF
proteomics ; chromatin-associated proteins ; detergent
heart failure ; mechanical support devices ; Cardiology-Cardiovascular Surgery Consensus report ; Heart failure
grounded theory ; heart failure ; implantable cardioverter-defibrillator
self-Care of Heart Failure index ;SCHfi ; psychometric profile
atrial fibrillation ; carvedilol ; metoprolol
ratio ; SDQT ; SD ; rr intervals ;SDrr ; qt ; heart rate variability
devices ; health care providers ; gastrointestinal bleeding
hospital ; readmission rate ; heart failure
Logistic regression models ; primary outcome ; secondary outcome of death
egf ; VAD group ; ecmo ;VAD group ; renal function
aUCs ; e-eseptal ; e-emean ; s'septal ; QRs
physical ; mortality ;HF ; noncardiologist ; physicians
LV ejection fraction ; PCWP
diuretics ;HF-related morbidity
readmission rate ; hospital stay ; congestive heart failure ; united states
IVc occlusion ; co correlated ; twist ; apical rotation ; RS ; RS synchrony
CHF ; ED ; CHF ; intubated
emergency department ; acute heart failure
zebrafish ; Nucleolin ; genomic reprogramming ; disease
physician adherence ; evidence
gls ;HR ; CV
sst2 ;low-dose BB ; sst2 ; high-dose BB
cardiac events
ejection fraction
incidence ; HF ; AMI ; mortality
exercise ; diet
mortality ; hospitals
nurses
HF ; drug treatment ; PAf ; biosynthetic enzymes ; lyso-paf-AT
cardiac magnetic resonance imaging ; t1 mapping ; invasive hemodynamic assessments ; baseline
HF ; preserved ejection fraction ; pEF
mouse ;HF ; hh ; salt loading ; uninephrectomy ; ANG II infusion
RAS ; neprilysin inhibition ; change ; chronic heart failure ; systolic dysfunction ; treatment
t1-mapping sequence ; tidal respiration ; administration ; gadolinium-chelate contrast agent
Medicare ; inpatient data ; HF admissions ; acute care hospitals ; united states
idiopathic dilated cardiomyopathy ; Tuscany
Morbidity ; mortality ;HFpEF ; HF ; EF
report ; DAPc ;dystrophin-associated protein complex ; sarcomeric ; baseline
low-dose dopamine ; low-dose nesiritide ; acute heart failure ; renal dysfunction ; ROse ; acute heart failure
catheter ablation ; atrial fibrillation ; heart failure ; ejection fraction
ecg ; accessory pathways ; ion channelopathies ; cardiomyopathy
heart failure ;HF
HF rats ; pyridostigmine ; basal heart rate ; vagal ; sympathetic control ; heart rate
intravenous iron ; exercise tolerance ; heart failure
erythropoiesis-stimulating agents ; anemia ; heart disease
bet ; bromodomain-containing protein 4 ;BR4 ; cardiac tissues
costs ; QuÃ©bec ; health insurance board ; costs ; Ontario case costing initiative
report ; mitral valve plasty ; mitral regurgitation
carvedilol ; metoprolol ; heart failure ; devices
HF ;heart failure ; t2d ;Type 2 diabetes ; Skm ;skeletal muscle
public health ; air pollution ; industrial areas ; cardiovascular health ; lead ; hospitalisation
molecular biomarkers ; pathophysiology ; chronic HF
cardiopulmonary exercise test ; quality of life ; muscular strength ; peak quadriceps force
Myocardial titin hypophosphorylation ; heart failure ; ejection fraction ; rat metabolic risk model
NT-probNP ; antibodies ; nonglycosylated ; nonterminal epitopes
university of connecticut Heart Failure Center ; cardiologist ; heart failure
baseline ; serum creatinine ; serum potassium
PD ; weight loss ; diuretic response ; peripheral edema
echocardiographic predictors ; cardiac resynchronization therapy ; cRT
HeartMate II lVAD ; centriMag RVAD
HF ; mi ; ejection fraction ;EF
anemia ; chronic heart failure ;HF
Hum-retn mice ; cardiac mRNA levels ; inflammatory ; cell adhesion genes ; Retn
chromatin subproteomes ; heart failure ; mechanisms ; proteins ; chromatin
HFpEF ; kccq ; health status
nbDMARD ; tNF antagonist ; baseline covariates
exercise ; heart failure
AF ablation
end-stage heart failure ; mechanical cardiac
Chronic heart failure ; transforming growth factor ; beta-dependent yield ; functional decline ; atrial explant-derived c-Kit
RV failure ; intrinsic left ventricular dysfunction
change
Mortality ; inpatient admissions ; hospital days ; emergency department ;ED
evidence gaps ; economic models ; lVAD
echocardiographic score ; cRT response
ejection fraction
If-channel inhibition ; hemodynamic status ; exercise tolerance ; heart failure ; ejection fraction
Cardiac insulin-resistance ; mitochondrial energy production ; systolic heart failure ; pressure-overload hypertrophy
nutritional abnormalities ; CHF
pigs ; vena cava ;IVc ; snared ; co
doxorubicin ; ip ; serum resistin levels ; Hum-retn mice
costs ; physicians
direct observation ; rheumatic ; MS ; mVA


HF rats ; pyridostigmine ; stroke volume ; ejection fraction ; cardiac output ; contractility ; left ventricle
myosin binding protein-C phosphorylation ; ser23/24 troponin I phosphorylation ; HF
aldosterone receptor antagonists ; morbidity ; mortality ; symptomatic systolic heart failure
uPR effectors ; protein kinase ; er kinase ;perk ; calreticulin ; chop ; HF
hFrEF ; exercise performance ; resting HR ; beta-blocker therapy
echodiographic measures ; N-terminal pro-brain natriuretic peptide ; inflammatory markers
cox hazard models ; ESRD ; corruption ; ESRD ; death ; ESRD
randomised-controlled trials ;RCts
heart failure ; heart failure ; nurses ; cardiology services ; mortality
heart failure ;HF ; cardiopulmonary exercise test ; anaerobic threshold
preoperative renal dysfunction ; stroke ; myocardial infarction ; heart failure ; caBG
XO inhibition ; cardiomyocyte bioenergetics ; LV ; chronic aCF
carvedilol ; thromboembolic events ; heart failure ; Î²2-receptor haplotype status
pyridostigmine administration ; methylatropine ; propranolol ; cardiac sympathovagal balance
baseline ; PAf ; activity ; metabolic enzymes ; heart failure
trastuzumab ; cardiotoxicity ; congestive heart failure ;CHf
Phosphodiesterase-2 ; failing hearts ; blunts ; beta-adrenergic responses ; cardiomyocytes
lipolysis ; energy expenditure ; natriuretic peptides ;NPs ; CC
cox proportional hazards models ; health behaviors ; health status
east ; rhythm control therapy ; AF ; cardiovascular complications ; AF
hearts ; Mena ; cardiac injury ; Mena ; HF pathophysiology
scn5a transcript ; uPR ; downregulation ; cardiac genes ; HF
gls ; index beat method ; cv ; cox proportional hazards
VAD group ; ecmo ; VAD group ; ecmo
tAPse ; PASp relationship ; downward regression line shift ; nonsurvivors ; PASp ; tAPse
right ventricular ;RV ; left ventricular assist device ; lVAD
albumin levels ; nutrition ; inflammation ; hepatic function ; lVAD implantation
ST2 ; discrimination
post-hCT CHF ; hCT ; City of Hope
Genes ; non-ischemic ; ischemic heart failure ; biomarkers ; heart failure
CHF-developed infarcted animals ; left ventricle ; end-diastolic pressure ; hg
health initiative ; HF
Peak oxygen consumption ; oxygen pulse
dialysis-dependent patients ; HF ; cRT implantation
RV ; pathophysiologic mechanisms ; RV dysfunction
recreational athletes ; sudden cardiac deaths ; atherosclerotic CAD
Ambient air pollution ; cardiovascular health ; trigger ; acute myocardial infarction
economic climate ; NHs ; behavioural-change interventions ; chronic disease ; exercise
deaths ; non-fatal stroke ; hospitalisations ; heart failure
therapeutic ; biomarkers ; molecular dysfunction ; chronic HF
kccq ; Kaplan-Meier curves ; death ; hospitalization
cRT-d ; IE ; defibrillator-only therapy
HR dynamics ; HR variability ; risk
diagnostic procedure
obesity ; diabetes mellitus ; metabolic risk factors ; comorbidities ; heart failure ; ejection fraction
therapy ; atrial fibrillation ; atrial tachyarrhythmias ; ATP ; shock therapy
hypoalbuminemia ; postoperative mortality ; left ventricular assist device ; lVAD
AMI ; heart failure ; kidney infection ; UTI
cardiopulmonary exercise testing ; echocardiographic assessment ; myocardial function ; left ventricular filling ; exercise
percutaneous coronary revascularization ; hemodynamically stable ;ICU
speckle tracking echocardiography ;STE ; biVP ; right ventricular pressure overload ;RVPO
pathophysiologic mechanism ; renal underperfusion ; renin- angion-aldosterone pathway
Olmsted County ; Minnesota ; MI ; HF
global proteomics ; pathway analysis ; pressure-overload-induced heart failure ; mitochondrial-targeted peptides
neurohumoral blockers ;HF ; co-morbidity burden
odds ratio ;hazard ratio ; death ;HF ; AMI
rule ; CAD ; CAD
inhibition of vascular endothelial growth factor ;VEg ; transition ; compensatory hypertrophy ; cardiac failure
Age-dependent effect ; left ventricular ejection fraction ; long-term mortality ; heart failure ; Heart Failure Survey ; irrael
collected ; medical hospitalization ; HF
IC ; multicenter Automatic Defibrillator Implantation ; Trial-Cardiac resynchronization Therapy
Testosterone therapy ; exercise rehabilitation ; chronic heart failure ; low testosterone status
health Buddy program ; chronic obstructive pulmonary disease ; mortality ; congestive heart failure
RAS ; doppler ultrasonography ; tomographic angiography ; magnetic resonance angiography
nicorandil ; cardioprotection ; apoptotic signaling pathway ; DNA fragmentation ; mitochondrial ultrastructural changes
atrial fibrillation ;AF ; heart failure ;HF ; stroke ; anticoagulation
echocardiographic score ; LV reverse remodeling
perk inhibition ; full-length scn5a ; kv4.3 mRNA levels ; na+ channel mRNA splice
bottleneck stent ; myocardial infarction ; antiplatelet medication
sex ; EF ; bNP ; HF ; bNP ; sex ; EF
Trastuzumab ; CHF ; nontrastuzumab ;hazard ratio ;HR
Rad variant ;Q66p ; congestive heart failure
salt loading ; uninephrectomy ; ANG II infusion mouse model ; cardiac function ; mice ; HF
Mena expression ; HF ; Mena ; cardiac pathophysiology
LVEF ; long-term mortality ; hospitalization ; acute decompensated HF
Fontan failure ; circulatory derangement ; hemodynamic ; portal hypertension ; cardiac output
HF ; index AMI ; adjusted hazard ratio ; mortality
systolic heart failure ; spironolactone
uPR ; na+ channel mRNA splice ; cardiac ; na+ current ; HF
diuretic efficacy ; adverse neurohormonal activation ;congestion-like symptoms ; fluid overload
BETs ; transcriptional pause release ; transcription ; pathological stress
evidence ; lVAD ; transplantation eligibility status ; budget
LVEF ; LVEF
apoptosis ; pathogenesis ; heart failure
function enrichment ; programmed cell death ; degs
eCG ; atherosclerotic CAD ; sudden cardiac death
HR reduction
ANS mice ; LV ; lung weight
atrial fibrillation ; atrial fibrillation ; Stroke prevention Trial
Frailty ; heart failure ;HF ; biological
MS ; valve plasty ; annular size reduction ; degenerative MR ; LV
idiopathic dilated cardiomyopathy
right ventricular ;RV ; body composition ; advanced heart failure ;HF
american college of Cardiology ;American Heart association ; RAS ; RAS
arn ; cardiovascular mortality ; hospitalization ; heart failure
peak work rate ; peak quadriceps force
implantable cardioverter-defibrillator deactivation ; physicians ; heart failure
EO-cFUs ; cd34 ; vegFR2 ; cells ; nondiabetic
report ; MS ; valve plasty ; degenerative MR ; LV ; disease
exercise ; anaerobic metabolism ; peak respiratory
exercise training ;HF ; exercise training ; therapy
myocardial DD ; muscle strip stiffness ; titin hypophosphorylation
NP measurement ; POc measurement ;NPs ; clinical care delivery
etiology ; comorbidities
physicians ; readmission rates
evidence points ; intestinal morphology ; permeability ; absorption function ; CHF
proteins ; altered expression ; cardiac hypertrophy ; proteins ; Nucleolin
benefits ; randomized trials
Blood pressure ; arm cuff ; stroke volume ;SV ; ejection fraction ; end-diastolic volume ; echocardiography
Kansas City ; Cardiomyopathy Questionnaire ; kvq ; HF ; EF ;HFpEF
biventricular ; hybrid system ; HeartMate II ; lVAD ; centriMag ; right ventricular assist device ; roVAD
Tricuspid annular plane systolic excursion ; pulmonary arterial systolic pressure relationship ; heart failure ; right ventricular contractil
fibrosis ; heart failure ; myocardial tissue ; left ventricular tissue ; trichrome blue ; histologic
bt ; DT ; cost-effectiveness limits ; bt ; standard practice
expenditure ; health per capita ; gross national income per capita ; HF ; LA
borderline
blood pressure control ; lipid-lowering therapy ; smoking cessation ; foundation of management ;RAS
SDQT ; HFVT ; HFVT ; hNorm group ; fixed-rate atrial pacing
cost-effectiveness ratios
AF ; pharmaceuticals ; hff
cRT-d ; heart failure ; death
bn ; inhospital mortality
t1-mapping technique ; diffuse myocardial changes ; heart failure ; contrast agent ; breath-holding
Implantable cardioverter-defibrillators ;ICds ; cardiac resynchronization therapy ; cRT
ventricular assist device ;VAD ; extracorporeal membrane oxygenation ; ecmo ; renal function
Vascular endothelial growth factor blockade ; beta-blocker therapy ; cardiac function ; angiogenesis ; remodeling ; heart failure
NT-probNP levels ; plasma ; dyspnea ; left ventricular dysfunction ; admission ; ED
contractile function ; LV dilatation ; LV ; end-diastolic pressure ;wall stress ; lung weight
Circulating progenitor cells ; cps ; endothelial repair ; cardiovascular diseases
HF-ACtion cohort ; baseline ; hgb ; baseline ; HRQoL ; kccq
pathological remodelling ; heart ; cardiac hypertrophy ; HF ; death ; fibrosis ; inflammation
snp ; Ka renal chloride channel gene ;clnKA
HFpEF ; echo-doppler cardiography ; invasive haemodynamic assessment
LV remodeling ; diastolic properties ; XO inhibition ; hospitalizations ; heart failure
RAS- ; Î²-blocker uptitrations ; hFrEF ; HFpEF
cardiac magnetic resonance ; amyloidotic pattern ; multiple myeloma ; osteomedullary biopsy
low-sodium DASh ; diet ; diastolic function ; ventricular-arterial coupling ; hypertensive heart failure ; ejection fraction
Yorkshire swine ; pacemakers ; ventricularly paced ; induce heart failure
multiparametric echocardiographic score ; reverse remodeling ; cRT
isolated heart rate ;HR ; ivabradine ; afterload ; patients ; systolic heart failure
biomedical treatment ; CHm ; biomedical treatment ; dm ; heart failure
cardiovascular outcomes ; Renal Atherosclerotic Lesions ; coRAL ; stenting ; RAS
centrifugal flow pump ; hemocompatibility ; magnetically levitated rotor ; blood-flow paths ; artificial pulse
mitochondrial complex ; activity ; post-aac ; ratio of phosphocreatine ; ATP
Mediterranean and Dietary Approaches to stop Hypertension ;DASh ; diet scores ; mortality ; postmenopausal women ;HF
left-to-right interatrial shunting ; heart failure ; ejection fraction
mortality ; heart failure ;HF ; implantable cardioverter defibrillators ;ICds
physical ; patients ; outcomes ; medically managed diseases ; HF
frail ; intermediate frail ; biological
eplerenone ; HF-ref ; inducing hyperkalemia ; wRF
emergency department ; acute heart failure ; aHF
RM ; discharged ; admission ; heart failure
LBb ; implantable cardioverter defibrillator-CRT ; primary outcome
standard error of measurement ; md
embryonic gene programs ; pathological heart disease ; transcription factors driving
hff ; outcome-monitoring phase ; cardiac event
sst2 ; low-dose BB ; sst2 ; high-dose BB ; intermediate odds ratios ; cardiovascular events
skeletal muscle sarcomere ; heart failure ; type 2 diabetes ; epicatechin-rich cocoa
QRs morphology ; cardiac resynchronization therapy ; cRT
exercise-induced PASp ; hg ; PASp
heart failure ; hypertension ; mitral regurgitation ; mitral stenosis ; medical ; heart failure
power systems ; NP levels
mortality ; readmissions ; costs
lb ; QRs ; implantable cardioverter defibrillator-CRT
echocardiography ; cardiac diameters ; cardiac function ; vehicle-treated rats
electronic databases ; MEDline ; EMBAse ; PsycINFO

factorial trial ; medical center
ST2 ; cardioprotective signaling ; myocardium ; biomarker ; heart failure ;HF
systolic HF ; cXL-1020 ; left ; right heart filling pressures ; systemic vascular resistance ; cardiac ; stroke
cardiovascular death ; stroke ; heart failure ; myocardial infarction
Cardiac-resynchronization therapy ; cRT ; chronic systolic heart failure ; QRs
perk activation ; scn5a ; kv4.3 ; mRNAs ; transient receptor potential cation channel ; m7 ;TRp7) ; mRNA
implantable cardioverter-defibrillator ; Heart function Clinic ; university health network ; toronto
exercise-induced PASp ; pulmonary hypertension ; right ventricular contractile reserve
MI ; animals ; metoprolol ; plasma norepinephrine ; dopamine ; epinephrine
antagonists ; inhibitors ; renin-angiotensin-aldosterone ; sympathetic nervous systems ; CHF
outpatient assessments ; heart failure ; hospital discharge ; readmissions
antiplatelet agents ; anticoagulants ; vascular diseases
Fontan failure ; hemodynamically ; heart failure ; systemic vascular resistance ; sVR ; cardiac index
myofiber dynamics ; myofiber shortening ; emd ; dyssynchronous HF
ankle-brachial index ; pulse-wave velocity ; coronary artery calcium scores
truncated na+ channels ; unfolded protein response ; uPR ; scn5a ; electric remodeling ; HF
intermacs ;Interagency Registry for mechanically assisted Circulatory support
international right Heart foundation working group ; defects ; right heart failure
cardiac hypertrophy secondary to pressure-overload ; abdominal aortic constriction ; aac
HF ; HF ; epidemiology ; SH ; rheumatic fever
caloric restriction ;diet ; aerobic exercise training ;exercise ; exercise capacity ; QOL ; hff
chronic heart failure ;HF ; hemodynamic disorder ; syndrome ; interconnected molecular pathways
guideline-recommended medications ; heart failure ; ejection fraction
HFpEF ; diastolic filling time ; heart rate
mice ; cardiac myocyte-specific Mena overexpression ;TTA ; tgtetMena ; cardiac pathology
allopurinol ; LV contractil ; XO-mediated ROS ; myofilament ; sensitivity
rate ratio ; therapy ; comorbidities
AF ; heart failure ; financial burden
rehospitalization ; Medicare ; hospital claims ; Medicare ; post-acute care transfer policy
heart failure ; compliance ; etidronate ; alendronate
metabolic exercise ; cardiac ; kidney index score
physical activity ; cRF ; HF mortality
et ; HDl-mediated protective effects ; molecular pathways ; chronic heart failure ;CHf
physicians ; advanced heart failure
isolated heart transplant ; ect
body weight ; FM ; fm ;cc

left ventricular ejection fraction ; left ventricular diastolic end diameter
eccentric ; concentric left ventricular hypertrophy ; heart failure ; ejection fraction
left ventricular ejection fraction ; heart failure ; preserved ejection fraction ;HFpEF
Î²-adrenergic receptor blocker therapy ; myocardial perfusion ; neoangiogenesis ; failing heart
baseline ; hgb ; baseline ; kccq scales ; hgb ; exercise training ; HRQoL
mechanisms ; bone morphogenetic protein ; expression ; rRNA transcription ; shift ; heterochromatic chromatin
low-dose dopamine ; nesiritide ; decongestion ; renal function
actin cytoskeleton ; mitochondrial function ; intermediate metabolism ; glycolysis ;gluconeogenesis ; citrate cycle
elevated resistin ; anthracycline-induced cardiotoxicity ; heart failure ; macrophages
extracellular matrix ; left ventricular biopsies ; tissueFAXs technology
systolic HF ; Danish Heart Failure database ; new-onset ESRD ; Danish Registry on Dialysis
left ventricular assist devices ; lVADs ; advanced heart failure ; pump dysfunction ; pump replacement
bp ; diastolic dysfunction
hART ; HFpEF ; HF ; ejection fraction ;HFrEF
imaging techniques ; systolic function ;HFpEF ; long axis function ; exercise
HF ; odds ratio ; 28-day mortality ; hazard ratio ; mortality
AAs ; HF ; hyperkalemia ; hypokalemia ; spironolactone ;AAs
receptors ; g-protein-coupled receptor kinase-2 ; desensitization ; downregulation
NT-probNP assay ; nonterminal epitopes ; central glycosylated
scn5a ; angII ; hypoxia ; expression ; exogenous variants induced ; uPR ; downregulation ; na+ current
ST2 ; amino-terminal pro-b-type natriuretic peptide
sst2 ; high-dose BB ; sst2 ; low-dose BB ; cardiovascular event
guideline ; anemia ; iron deficiency ; MEDline ; cochrane Library
neurohormones ; adipokines ; body composition ;cc ; fat free mass ; fm ; fat mass ;FM
cardiac plasma membrane levels ; s1p1 ; counterbalance ; Î²1AR overstimulation ; heart failure
Sprague-Dawley rats ; sham ; aCF ; allopurinol
t1 ; myocardial collagen ; myocardial delayed enhancement imaging
saxagliptin ; sitagliptin ; follow-up
fully magnetically levitated lVAS ; mortality risk ; Seattle Heart Failure model-predicted survival
metric ; hospitals
kccq ; internal consistency ; HFpEF ; ronbach
implantable cardioverter defibrillator-CRT ; non-LBb ; QRs duration
principal mechanisms ; clinical trials
alendronate ; etidronate ; raloxifene-treated
Chemotherapy ; trastuzumab ; CHF ; international classification of Diseases ; healthcare Common procedure
heart failure ;HF ; therapies ; HF ; left ventricular ejection fraction ;LVEF
conscious dogs ; tachypacing-induced HF ; cXL-1020 ; contractility ; end-systolic elastance ; venoarterial dilation
cRT ; hazard ratio
MT group ; operation
cox proportional hazards ; death ; transplantation ; LV assist device implantation ; heart failure
Nicorandil ; phosphocreatine ; adenine nucleotides ; mitochondrial oxidative phosphorylation capacity ; creatine kinase activity
correlation coefficient ; icc ; kappa coefficient ; standard error of measurement ; relative minimal detectable change ; md
Hospitalized Heart Failure ; Saxagliptin ; sitagliptin ; antihyperglycemic drugs
race ; exercise training ; chronic heart failure ; Heart Failure ; exercise TraiNing ;HF-ACtion
biomedical treatment ; CHm ; biomedical treatment ; dm ; heart failure ; PubMed
stockholm national inpatient Registry ; rehospitalization ; stroke ; myocardial infarction ; heart failure ; cab
biventricular pacing ; biVP ; cardiac output ; co ; cardiac surgery
New York Heart association ;NYha ; chronic heart failure ; ejection fraction
AlphaLISa immunoassays ; antibodies ; termini ; circulating NT-probNP
creatinine ; bp ; furosemide dose ; oxygen flow ; dobutamine ; norepinephrine
expression ; mistargeting ; regulation ; Rad Q66p ; rGK protein
Myocyte hypertrophy antecedent to heart failure ; gene expression ; coordinate DNA
Catheter ablation ; AF ; compensated HFPEF ; left ventricular ;LV ; ejection fraction
Cardiology practices ; national Cardiovascular Disease Registry ; practice innovation and Clinical Excellence
transitions of care ; congestive heart failure ; midwestern state ; south dakota
sts HH ; medical ; office hours ; all-cause mortality ; discharged patients ; heart failure
induced myocardial infarction ; heart failure rats ; bisoprolol ; vehicle
transitions of care
CHF ; cardiac explant ; c-Kit ; mechanisms ; regulation
tachycardia ; intravenous atropine ; cardiac vagal tone ; CHF-DNx ; CHF-inv
cardiomyocytes ; mechanical ; humoral stimuli ; myocardium ; conditions ; workload
biological ; deficit index ; medical records ; frailty
BB therapy ; sst2 measurement ; chronic heart failure ; BB
ESRD ; outpatients ; systolic HF ; egf
tAPse ; PASp relationship ; length-force relationship ; RV ; LV dysfunction
TUNEL assay ; apoptotic cells ; TUNEL-positive cells
hno donor ; myocardial function ; first-in-man evidence ;HF
biventricular support ; RVADs
Peritoneal dialysis ;PD ; diuretic resistant volume overload ; heart failure ;HF
left-to-right interatrial shunting ; heart failure ; ejection fraction ; proof-of-principle
report ; hno donor ; cXL-1020 ; isolated myoctyes ; intact hearts ; heart failure ;HF
physical ; bmi ; weight ; heart rate ; rhythm ; lying ; standing blood pressure ; auscultation ; valvular disease ; pulmonary congestion
myocardial extracellular matrix ; cardiac magnetic resonance t1 ; pathobiology ;pathophysiology
aldosterone antagonist therapy ; chronic advanced heart failure ; post-myocardial infarction ; heart failure ; ejection
Nicorandil ; heart rate ; aortic blood flow ; mitochondrial oxidative stress induced ; doxorubicin ; cardiotoxicity
heart failure ; left ventricular ejection fraction ; spironolactone ; Kaiser Permanente Northern California
SDQT ; hawt ; hNorm group ; Î²-adrenoceptor blockade ; esmolol
heart failure ; CHARM programme ;Candesartan in Heart Failure assessment of reduction in Mortality and Morbidity
heart failure ; preserved ejection fraction ; hff ; heart failure ; overweight ; obese
Renal dysfunction ; heart failure ;HF ; end-stage renal disease ; erd
regression analysis ; echocardiographic score ; LV reverse remodeling ; LV ; end-systolic volume
Peripheral artery disease ;PAD ; heart failure ;HF ; HF ; PAD
disease groups ; heart failure ;HF ; acute myocardial infarction ;AMI ; pneumonia
peripheral muscle pump ; cardiac filling ; exercise ; subpulmonary ventricle ; Fontan circulation
preoperative renal dysfunction ; cardiovascular events ;stroke ; myocardial infarction ; heart failure ; isolated coronary artery bypass grafting
Fontan ;PF ; catheterization
ms ; subvalvular ; dynamic ; annular MS ; fixed ring size
ventricular assist devices ; cardiac nurses ; gastrointestinal bleeding
Lancet ; Anoop Shah ; air pollution ; heart failure
anemia ; HF ; health-related quality of life ;HRQoL ; HF
cell therapy ; chronic heart failure ;CHf ; disease ; explant-derived progenitor cells
mri-based models ; dyssynchronous nonfailing ; HF ; canine electromechanics
american college of Physicians ; aCP ; evidence ; anemia ; iron deficiency ; heart disease
exercise ; cell senescence ; active ; malignancies ; cancer ; prostate ; colon ; osteoporosis ; depression ; dementia
drug-free
race ; chronic heart failure ;HF ; exercise
histological ; capillary ; coronary perfusion ; ad-flk rats ; b-treated ; ad-c rats
physician ; mortality ; internists ; cardiologists
shuttle walk test ; body mass ; hand grip strength ; baseline
protocol-driven POc testing ; NP ; ED
Troponin t ; N-terminal pro-B-type natriuretic peptide ; heart failure ; atherosclerosis
tachycardic response ; methylatropine ; vagal tone ; bradycardic response ; propranolol
acute RV failure ; chronic pulmonary arterial hypertension ;PAh ; acute pulmonary embolism
cardiac resynchronization therapy ; cRT ; mild heart failure ;HF ; QRs ; ejection fraction ;EF
Fractional flow reserve ; positron emission tomography imaging ; ischemia ; bottleneck stenting covering ; left ventricle ; LAD
mitochondrial oxidative phosphorylation capacity ; creatine kinase activity ; oxidative stress markers ; DNA fragmentation ; ultrastructural
cox regression ; spironolactone ; death ; hyperkalemia ; acute kidney injury
mortality ;hospitalization ; mortality ; cardiovascular mortality ;HF hospitalization ; cox models ; exercise training
cardiac transplant ; ect ; transplant pool ; donors ; transplant
exercise ; medical Therapies ; Cardiac function ; shortness of Breath due to Lung congestion ;ACTRN
mi-induced decreases ; septum ;systolic ; thickness ; LV ; posterior wall thickness ; LV internal diameter ; metoprolol
hff ; caloric restriction ; aerobic exercise training ; peak VO2
economic ; Patient management Interventions ; Heart Failure ; cost-effectiveness ; disease management programs ; heart failure
HF registry ; HF ; EF ; HFpEF
BAT ; N-terminal pro-brain natriuretic peptide ; HF
HR variability ; mortality ; AMI ; CHF ;LV dysfunction
neprilysin inhibitors ; natriuretic peptide system ; breakdown ; atrial natriuretic peptide ; b-type natriuretic peptide
postoperative survival ; preoperative hypoalbuminemia ; normal albumin
RV failure ; pulmonary embolism ; mortality
bundle branch block ; electrical activation ; dyssynchronous heart failure ;HF ; electromechanical behavior ; heart
heart failure ;heart team ; cardiologists ; cardiovascular surgeons ; medical staff
Baroreflex sensitivity ; heart rate variability ;HRv ; CHF-inv group ; sham-inv ; sham levels ; renal DNx
bisphosphonates ; alendronate ; etidronate ; heart failure ; compliance
nurse ; cognitive impairment ; hospitalization ; physician ; discharge ; heart failure
HF-action ; HF ; ejection fraction ; exercise training
herbal medicine ;CHm ; adjunctive treatment ; dilated cardiomyopathy ;DCm ; heart failure
serum resistin levels ; anthracycline-containing chemotherapy ; cardiotoxicity
sst2 ; high-dose BB ; cardiovascular event rate
Rad Q66p ; cardiomyopathy ; mechanism ; l-type channel-dependent processes
altered ventricular structure ; both geometry ; fiber ;sheet orientation
baseline ; SDQT-to-SDrr ratio ; HFVT ; HFVT ; hNorm groups
renin-angiotensin system blocker ; beta-blocker therapy ; heart failure ; left ventricular ejection fractions
functional electrical stimulation ; peripheral muscles ; endothelial function ; heart failure ; left ventricular ejection fraction
baseline ; cardiac transplant ; ect
diastolic dysfunction ; pathophysiology ; HFpEF ; non-diastolic abnormalities ; cardiovascular function
emd ; dyssynchronous HF
hypertension ; compensated HFPEF ; DASh ; srd ;target sodium
doxorubicin-induced cardiotoxicity ; Hum-Retn mice ; littermate controls ; human resistin ; retn
arrhythmia substrate ; AMI ; HR variability ; arrhythmia events
dietary ; heart failure ;HF ; non-HF ; evidence ; dietary patterns ; HF
HF ; am ; pna ; mortality
hypertension ; hg ; diabetes mellitus ; systolic ; diastolic murmurs
tpse ; PASp relationship ; nonsurvivors ; hFrEF ; HFpEF
epigenetic ; proteins ;histone acetyltransferases ; epigenetic ;erasers ;histone deacetylases ; cardiac
NT-probNP levels ; all-cause mortality ; acute HF
haematopoetic cell transplantation ; ght ; congestive heart failure ;CHf ; pre-HCT ; anthracyclines
cardioprotective effect ; nicorandil ; hemodynamic alterations ; mitochondrial dysfunction induced ; cumulative administration ; doxorubicin
in vivo inhibition ; mir-25 ; antagomir ; spontaneous cardiac dysfunction ; murine myocardium ; heart failure
carvedilol ; Î²-blocker ; Î²-blocker ; metoprolol ; thromboembolic events ; heart failure
cox regression models ; propensity score decile ; oral glucocorticoid ; HF ; loop diuretics
preoperative albumin ; mortality ; lVAD implantation ;hazard ratio
dyssynchronous HF ; electromechanical delay ;EMd ; myocyte depolarization ; myofiber shortening onset
Beta blockers ; readmissions ; heart failure ; ejection fraction ;HFrEF ; heart rate ;HR
bleeding ; driveline infection ; gastrointestinal bleeding ; debilitating stroke ; Rankin Score
Dialysis ;HF
functional electrical stimulation ; fes ; exercise capacity ; emotional stress ; endothelial function ; chronic heart failure ; impaired systolic function
ejection fraction ; cardiac index ; inotropes ; inotrope-dependent ; medical
systolic heart failure ; QRs duration ; cRT ; rate of death ; hospitalization ; heart failure
high-density lipoprotein ;HDl ; endothelial-protective effects ; endothelial cell ;EC ; nitric oxide ;NO
8-fluo-cAMP binding ; wild type ; phosphomimic ser77 ; ser80 ; ser83 ; mutant ; RIÎ± proteins ; kd ; double mutant ; wt RIÎ±
outcome ratings ; admission to discharge ; hospitalized older adults ; heart failure ;HF ; Nursing outcomes classification ;noc
insulin resistance ; type 2 diabetes ; insulin receptor substrates ;IRs1 ; irs2 ; insulin-signaling ; cellular metabolism
dgs ; non-ischemic ; ischemic heart failure ; heart failure
hh ; saxagliptin ; sitagliptin ; antihyperglycemic agents
QRs morphology ; cardiac resynchronization therapy ; resynchronization-Defibrillation ; Ambulatory Heart Failure Trial ;RAFt
heart magnetic resonance imaging ; chelation choices ; compliance ; heart failure ; arrhythmias
EDs ; heart failure home ; ED cases ; readmissions ; ED
anticoagulation ; rate control ; cardiovascular complications ;stroke ; cardiovascular death ; acute heart failure ; atrial fibrillation ;AF
nitroxyl ; hno ; Angeli ; salt ; inotropic ; lusitropic ; vasodilator effects ; cAMP
Gene expression ; Bax ; bcl-2 mRNA expression ; heart failure ; ratio ; bcl-2/Bax
cps ; early-outgrowth colony-forming units ;EO-CFUs ; circulating ; vEGFR2 ; cd133
ejection fraction ;EF ; pre-PD ; NYHA class IIIb ; right ventricular dysfunction
evidence ; continuous-flow lVADs ;HeartMate II ;HM II ; HeartWare ; bt ; DT
emergency room practice ; undiagnosed heart disease ; HF ; surgical palliation
cRT-d ; IE ; IC ; cRT-d ; IEs
Frailty ; biological phenotype ; weak grip strength ; physical ; activity ; unintentional weight loss
transplant ; PD ; HF volume management ; pre-PD
SAF ; abnormal liver texture ; nodularity
biomarker studies ; biomarker-guided clinical trial design ; therapeutic potential
report ; right atrial myxoma ; embolism ; pulmonary arteries ; right atrial mass removal ; pulmonary embolectomy
acute right heart failure ; therapy refractory cardiogenic shock ; heart ; corporeal membrane oxygenation ; ecmo ; cp ;ICU
b treatment ; cardiac VEGF expression ; Akt ; endothelial NO synthase activation ; b-treated ; failing hearts
heart failure ; left ventricular systolic dysfunction ; BB
baseline ; post-DASh ; srd ; central blood pressure ; radial arterial tonometry ; cardiovascular ; echocardiographic measures
cardiac insulin-resistance ; post-aac ; insulin-stimulated rates ; glycolysis ; glucose oxidation ; plasma membrane translocation ; glucose transporter
Gene expression profile ; gse9128 ; Gene Expression Omnibus ; non-ischemic heart failure ; ischemic
exercise-induced PASp ; right ventricular contractile reserve ; exercise-induced PASp
Gene expression profiling ; cultured cardiomyocytes ; jq1 ; drug abrogated ; induction ; phenylephrine-induced genes
psychosocial factors ; exercise adherence ; Heart Failure Patients ; Heart Failure ; exercise training ;HF-ACtion
ST2 ; functional capacity ; outcomes ; ambulatory patients ; HF
baseline ; EF ; blinded core laboratory
cardiovascular diseases ; heart failure ;HF ; HF
bp ; bNP ; inhospital mortality
quality of life ; all-cause mortality
DASh ; diet scores ; mortality ; HF ; Mediterranean diet scores
skeletal muscle mass ; relative appendicular lean mass index ; z-score
CLnKA polymorphism ; arg83gly ; heart failure ; glomerular filtration rate ; reNAStur
intubation rates
black race ; chronic HF ; exercise performance ; HF ; mortality ; exercise training
hearts ; fish ; Nucleolin ; chamber patterning ; functional deficits ; cardiac looping ; myocyte differentiation
wasting of fat ; lean mass ; fat loss ; enhanced catabolism ; adipose tissue ; cardioprotective ; HF
drugs ; heart failure ; biomedical reasons ; nonprescribing
hff ; exercise protocol ; respiratory gas ; baseline
hearts ; tgttMena mice ; wild-type littermates ; heart mass ; transgenic mice
raloxifene ; mechanism of action ; heart failure
derivation cohort ; coronary angiography ; systolic HF ; unclear etiology ;ejection fraction
arterial elastance ; ea ; end-systolic elastance ; ees ; ventricular-arterial coupling ; ratio ; ees ; ea
heart failure ; left ventricular ejection fraction ; fes ; exercise capacity ; emotional status ; endothelial function ; HFpEF
extracorporeal life support ;bridging therapy ; acute ischemic right heart failure ; refractory cardiogenic shock ; reperfusion therapy
HF ; ejection fraction ;HFrEF ; HF ; preserved ejection fraction ;HFpEF
Cells ; angiotensin II ; angII ; hypoxia ; activators ; abnormal scn5a ; mRNA splicing ; induced ; scn5a
rhythm control therapy ; rhythm control therapy ; antiarrhythmic drugs ; catheter ablation ; electrocardiographic device ; rhythm
expenditures ; noncardiovascular diagnoses ; implantable cardiac arrhythmia devices ; noncardiovascular drugs
change ; readmissions ; hospital quality improvement
contractility ; ventricular-arterial coupling ; ivabradine-treated
power spectral ; low-frequency ; high-frequency ;LF ;HF ratio ; CHF-inv ; sham-inv ; sham levels ; DNx

cardiac magnetic resonance ; postcontrast t1 ; hff ; postcontrast t1 ; hff
myocardial DD ; collagen deposition ; titin modification ; obese ; diabetic zSF1 rats ; heart failure ; ejection fraction
HF-action ; left ventricular ejection fraction ; New York Heart association ; IV HF ; exercise training
adverse event rates ; acute myocardial infarction ; congestive heart failure ; in-hospital adverse events
np-terminal pro-b-type natriuretic peptide ;NT-probNP ; misdiagnosis ; heart failure ;HF
Macrophages ; cardiomyocytes ; Hum-Retn mice ; doxorubicin ; hRetn ;human resistin ; mRNA ; protein expression
plasma collected ; HF ; immunoreactive NT-probNP ; NT-probNP
EH ;HFpEF ; pathophysiologically ; HF ; EF ;HFrEF ; hFrEF ; therapy
withdrawal of sympathetic tone ; parasympathetic tone ; heart rate response ; intravenous bolus of metoprolol ; atropine
FM ; plasma NPs ; adiponectin ; baseline ; FM ; fm ;NPs ; adiponectin
lVADs ; CF ; HeartMate II devices ; Thoratec Corp ; Pleasanton ; Calif ; hVAD ; HeartWare intl ; intl ; Framingham ; mass
beat-to-beat QT interval ; eCGs ; baseline ; atrial pacing ; esmolol ; isoprenaline ; atropine infusion
rule ; CAD ; angiography ; systolic HF ; cost
frailty ; health ABC ; short physical performance Battery ; hawt Battery ; Gill index ; HF
HF ; QRs prolongation ; LVEF ; cRT ; reverse remodeling ; LV ; systolic dysfunction
HF ; t2d ; ERC ; treadmill testing ;VO2max ; oxygen consumption ; Skm ; biopsies
Catheter-based percutaneous revascularization ; angioplasty ; stenting
hospital ; gastrointestinal bleeding ; died ; incessant ventricular tachycardia storm ; terminal heart failure
load-corrected chronotropic response ; heart rate ; exercise ; baseline ; follow-up tests ; heart rate ; exercise
transcriptional ; cardiac tissue ; mice ; TAC ; sham-operated ; jq1 ; vehicle ; BET inhibition ; pathological cardiac gene expression programme
epigenetic readers ; cardiac biology ; cardiac gene control ; chromatin-dependent signal transduction ; pathological gene expression ; HF progression
cox-proportional hazard models ; negative binomial regression models ; health
Heart failure ; noncardiac ; cardiac transplant
Peak oxygen consumption ;VO2max ; resting HR
cutoff value ; admission ; NT-probNP ; survival ; ED ; acute HF
conditional gene-targeted hand2 ; pressure-overload-induced hypertrophy ; fibrosis ; ventricular dysfunction ; induction ; fetal gene
Systolic blood pressure ; left ventricular ;LV ; hypertrophy ; ANS
RV ; lVAD ; cardiogenic shock ; myocardial infarction ; chronic decompensated heart failure
PF cohort ; New York Heart association ; SAF ; PF
HF ; AMI ; adjusted odds ratio
EDs ; heart failure ; ED
report ; conditions ; turkey
administrative ; health ; HF ; AMI
physicians ; mortality ; physicians ; low-volume hospitals
medication
nursing-sensitive outcome measures ; science ; treatment ; older adults ;HF
free-breathing pulse sequence ; myocardial t1 ; swine model ; tachycardia-induced heart failure
non-frail ; Gill index ;HF

Chronic Î²-AR stimulation ; catecholamine infusions ; pde2 expression ; cAMP hydrolytic activity ; blunted cardiac Î²-AR responsiveness
Xanthine oxidase ;XO ; left ventricular ;LV ; myocytes ; volume overload ;VO ; mitral regurgitation ; aortocaval fistula ; acf
zf1 groups ; heart failure ; ejection fraction ; lung weight ; left ventricular ejection fraction ; left ventricular
chronic pAH ; hospitalized patients ; acute RV decompensation ; pharmacologic therapies ; RV failure management ; pAH
Chronic heart failure ;CHf ; multisystem disease ; anemia ; insulin resistance ; autonomic dysbalance ; cardiac cachexia
heart failure ; ejection fraction ;HFpEF ; health status
inhibitor jq1 ; BETs ; chromatin ; downstream signalling ; RNA polymerase II ;pol II
report ; ischemic-hypertensive cardiomyiopathy ; angina ; inducible myocardial ischemia ; coronary arteries
intestinal dysfunction ; disturbed intestinal barrier ; chronic inflammatory state ; catabolic ;anabolic imbalance ; cardiac cachexia ; CHF
RA ; methotrexate ; tNF antagonist ; non-biological disease ; antirheumatic drug ;nbDMARD
cyclic adenosine monophosphate ; cAMP ; cyclic guanosine monophosphate ; cgm ; signaling ; failing hearts
cox proportional hazards regression modeling ; ie ; hospitalization ; acute coronary syndromes ; coronary interventions
miRNAs ; noncoding RNAs ; regulate expression ; genes ; binding ; messenger RNA
catheter ablation ; atrial fibrillation ;AF ; heart failure ; preserved ejection fraction ; hff
HFpEF ; ivabradine ; placebo
mortality ; healthcare ; telehealth ; congestive heart failure ; chronic obstructive pulmonary disease ; diabetes mellitus
empirically ; heart failure ;HF ; acute myocardial infarction ;AMI ; pneumonia ; pna
nurses ; pathophysiology ; HF ; medical ; pathophysiologic state
NPs ; heart failure ; pulmonary embolism ; diabetes ; chemotherapy
Cardiac c-Kt ; cells isolated ; cardiac explant-derived cells ; cardiac functions ; myocardial infarction
sphingosine-1-phosphate receptor ; s1PR ; Î²1-adrenergic receptor ;Î²1AR ; g-protein-coupled receptors ; heart
EF ; LCx ; LAD ; stenting ; infarcted left ventricle ; LCx ; LAD
signalling cascades ; microRNAs ; expression ; bhlh transcription factor ; hand2 ; postnatal mammalian myocardium ; embryonic gene programs ; heart failure
BET ; bromodomain proteins ;BETs ; acetyl-lysine reader proteins ; HF pathogenesis ; HF
cardiac function ; echocardiography ; diastolic dysfunction ; systolic dysfunction ; ejection fraction
hART ; New York Heart association ;NYHA ; hospitalized ; HF ; self-management counseling ; primary outcome of death ; HF
mv ; surgical ring implantation ; leaflet motion ; leaflet resection ; edge-to-edge anastomosis
EH ; LV compliance ;LV ; end-diastolic volume ; LV ; end-diastolic pressure ; hg Î² coefficient
e-septal correlated ; PCWP
Rad Q66p ; inhibitory actions ; Rad ; cav1.2 ; cav1.3 ; l-type channel isoforms ; heart
inappropriate therapy ; atrial fibrillation ; carvedilol ; metoprolol
ERC induced recovery ; DAPc protein levels ; sarcomeric microstructure ; markers ; Skm ; growth ; myofibre regeneration
gls ; LVEF ; cv events ; echocardiographic systolic parameters ; AF
cp-recommended pharmacological treatment ; device ; self-care education ; left ventricular function assessment
Nordic walking ; standard cardiac rehabilitation care ; functional capacity ; heart failure
Bradycardia induced ; intravenous metoprolol ; cardiac sympathetic tone ; CHF-inv rabbits ; sham-inv ; CHF-DNx
blood transfusions ; iron ; erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease ; transfusion
evidence ; erythropoiesis-stimulating agent therapy ; venous thromboembolism
influx ; voltage-gated ; plateau phase ; ventricular action potentials ; trigger ; excitation-contraction ;EC ; coupling ; myocardium
heart failure ;HF ; tumor necrosis factor ;TNf ; tNF antagonists ; HF
peak oxygen uptake ; metabolic exercise ; cardiac ; kidney index ; HF index
clinical ; genetic ; CHF predictive model ; curve ;AUc ; genetic ;AUc
percutaneous one-vessel model ; chronic myocardial ischemia ; stent coated ; polytetrafluoroethylene tube ; bottleneck
black race ; mortality ;hospitalization ;hazard ratio ; cardiovascular mortality ;HF
Centers for Medicare and Medicaid services ; cm ; hospital quality of care outcomes ; publicly ; mortality ; readmission rates ; penalties
Î²-blockade ; disease progression ; cAMP-dependent protein kinase ; pKA ; downstream ; Î²-adrenergic receptor activation ; post-translational states
right heart circulatory failure ; mechanisms of disease ; right heart
HF
Grading of recommendations assessment and evaluation ;GRADe
aldosterone antagonism ; heart failure ; aldosterone ; neurohormone ; electrolytes ; heart failure ; systolic dysfunction
AT1 receptors ; neprilysin blocks ; renin-angioten-aldosteron ;RAS ; axis ; natural vasodilatory ; diuretic effect ; natriuretic peptides
bp ; glomerular filtration rate ; hypertension ; transmitral e-wave ;early diastolic mitral annular velocity
ivabradine ; exercise capacity ; left ventricular filling ; heart failure ; ejection fraction ;HFpEF
medication ;nonadherence ; salt intake
HR variability ;turbulence ; HR variability ; turbulence ; cardiac patients
low-dose dopamine ; low-dose nesiritide ; renal function ; acute heart failure ; renal dysfunction
clinical studies ; HM II ; HeartWare patients ; economic evaluations ;HM II
death ; glomerular filtration rate ;odds ratio
creatinine ;hazard ratio ; post-transplant mortality
lVAD ; surgery ; albumin levels ; hypoalbuminemia
pathophysiological
cox proportional hazard models ; follow-up ; physician ; primary outcome of death ; urgent all-cause readmission
logistic regression ; rule ; CAD ; stenosis ; left main ;vessel ; CAD ; proximal left anterior descending artery
incidence and mortality outcomes ; heart failure ; acute myocardial infarction ; acute myocardial infarction ; western Australia
aldactone evaluation study ; chronic advanced heart failure ; aldosterone antagonist ; spironolactone ; mortality
mechanism ; surgery ; diastolic mitral valve tethering ; anterior leaflet opening ; papillary muscles ; left ventricular dilatation
hff ; sodium-restricted DASh diet ; ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling
signal transduction cascade ; transcription factors ; pathological changes ; cardiomyocytes ; transcription factors ; epigenetic changes ; chromatin
CHF ; hCT ; anthracycline metabolism ; iron homeostasis ; anti-oxidant defence ; myocardial remodelling
ecs ; HDl ; phosphorylation ; eNOS-Ser ; eNOS-Thr ; PKc-Î²II-Ser ; p70s6k-Ser
cRT on ; HF ; hospitalization ;hazard ratio ; LVEF
heart failure ; myocardial collagen ; tissue ; heart failure
administrative databases ; Alberta ; discharged alive ; hospital ; heart failure
mouse ventricular myocytes ; sarcomere ; transient
sts ; HH ; HM ; sts ; TM
low PASp ; walking distance
lVAD therapy ; transplantation eligibility status ; bt ; DT ; medical therapy
beta1-adrenergic receptor ; sphingosine-1-phosphate receptor ; s1PR ; reciprocal downregulation ; cardiac hypertrophic response ; heart failure ; s1PR1 ; cardiac gene therapy
radial artery tonometry ; admission ; PH ; ICU
cardiomyocytes ; pde2 activity ; cgm ; nitric oxide donors ; pde2 inhibition ; Î²-AR responsiveness
ejection fraction ; b-type natriuretic peptide levels ; heart failure ; inhospital outcomes ; guideline-Heart Failure Registry
Breast cancer ; Medicare coverage ; breast cancer ; chemotherapy ; sEER-Medicare ; Texas Cancer Registry-Medicare
eRK1/2 signalling ; signalosome ; scaffold protein drives ; kinases ; sequential phosphorylation
magnetically levitated centrifugal-flow chronic lVAS ; adverse event profile
l-dco mice ; cardiac ; iRS1 ; irr2 proteins ; heart failure ; impaired cardiac energy metabolism ; p38Î± ; mitogen-activated protein kinase
heart failure
hospitals ; heart failure ;HF ; conditions ; acute myocardial infarction ; pneumonia
carvedilol ; metoprolol ; implantable cardioverter-defibrillator therapy ; MADIT-CRT trial ;Multicenter Automatic Defibrillator Implantation ; Cardiac resynchronization Therapy
Caloric restriction ; aerobic exercise training ; Peak oxygen consumption ; quality of life ; Heart Failure ; Preserved ejection Fraction
left ventricular assist devices ; lVADs ; chronic end-stage heart failure ;bridge to transplantation ; bt ; transplant-ineligible patients ; destination therapy ;DT
right ventricular-pulmonary arterial coupling ;pulmonary vascular resistance ; right ventricular ejection fraction
implanted left-to-right interatrial shunt ; haemodynamic outcomes ; heart failure ; ejection fraction
relative risk ;RR ; heart failure ; bisphophonates ; crude rr ; confidence interval ; CI ; adjusted hazard ratio ;HR
aCP ; red blood cell transfusion strategy ;trigger hemoglobin threshold ; hemoglobin levels ; coronary heart disease
Medicare ; fee-for-service ; enrolled ; Centers for Medicare and Medicaid services ; propensity-score
acute heart failure ; renal dysfunction ; low-dose dopamine ; low-dose nesiritide ; decongestion ; renal function ; diuretic therapy
Rhythm control therapy ; AF ; atrial structure ; sinus rhythm ; delayed rhythm control ; rate control
kccq ; New York Heart association ; HFpEF ; HF ; EF
nicorandil ; doxorubicin-induced heart failure ; rats ; hemodynamic perturbations ; mitochondrial dysfunction ; ultrastructural changes ; antitumor activity
physician ; guideline ; heart failure ; Clinical practice guideline ;CPg ; outcomes ; heart failure ;HF
HF ; body composition ; skinfold thickness ; dual-energy x-ray absorptiometry ; echocardiography ; blood testing
cardiac insulin-resistance ; mitochondrial oxidative metabolism ; metabolic changes ; cardiac hypertrophy ; energy deficit ; hypertrophy ; heart failure
economic ; Patient management Interventions ; Heart Failure ; cost-effectiveness model ; cost-effectiveness ; disease management ; heart failure
Rad ; rg ; rem ; Rem2 ; Rad ; Gem ;Kir ; monomeric g proteins ; regulates ventricular action potential duration ; EC coupling gain ; cardiac l-type channel activity
breathing control ; cardiac arrest ; pulseless ventricular fibrillation ;PVf ; cardioverter-defibrillator device
mechanism ; surgery ; diastolic mitral valve tethering ; anterior leaflet opening ; papillary muscles ; left ventricular ;LV ; dilatation
pathophysiology ; heart failure ; preserved ejection fraction ; hff ; myocardial extracellular matrix accumulation
cox model ; PASp ; exercise ; peak o2 per kilogram ;hazard ratio ; peak o2 per kilogram ; PASp
Oral glucocorticoids ; dose-related gradient ; HF
HFPSI ; medical hospitalization ; HF ; outpatients ; HF ; health systems
HR ; ivabradine group ; ea ; TAC
guidelines-Heart Failure ; HF ; borderline ;EF
change ; peak VO2 ; change ; lean body mass ; change ; thigh muscle ;intermuscular fat ratio
testosterone ; exercise rehabilitation ; health outcomes ; CHF ; low testosterone status
ethnic groups ; CHm ; adjunctive treatment ; dm ; heart failure
carvedilol ; inappropriate therapy ; metoprolol ;hazard ratio
acetylcholinesterase inhibitor pyridostigmine ; sympathovagal balance ; cardiac remodeling ; cardiac function ; HF ; myocardial infarction
re-hospitalization ; admissions
cardiac arrest ; cardiopulmonary resuscitation ; cp ; posterior wall infarction ; cardiac centre
heart failure ;HF ; ejection fraction ;rEF ; renin-angiotensin system ;RAS ; Î²-blockers
uPR ; sn5a ; ventricular systolic HF ; induced pluripotent stem cell-derived cardiomyocytes ;hipsc-CMs
type 2 diabetes ; saxagliptin ; sitagliptin ; pioglitazone ; second-generation sulfonylureas ; long-acting insulin
evidence ; aCP ; erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease
hyperkalemia ; mineralocorticoid receptor antagonists ; race ; mineralocortic receptor antagonists ; heart failure ;HF
pde superfamily ; pde2 ; cgm ; cAMP hydrolysis ; cgm ; cAMP signaling
mitochondrial-targeted antioxidant ; protective peptides ; Szeto-Schiller ; ss20 ; cardiac function ; proteomic remodeling ; signaling pathways
cardiac sympathetic activity ; i-meta-iodobenzylguanidine ; i-miBG ; Î²-blocker
tpse ;longitudinal RV fiber shortening ; PASp ;force ; RV ; length-force relationship
cumulative urine volume ; decongestion ; change ; serum cystatin c ; enrollment ;renal function
brain natriuretic peptide ; bNP ; bNP ; bNP
LVEF ; reverse remodeling parameters ; HF ; hospitalization ;hazard ratio
Swedish web-system for enhancement and development of evidence-based care ; Heart disease ; Recommended Therapies registry ; primary isolated cab ; stockholm
np-terminal probNP ;NT-probNP ; midregional proANp ;MR-proanp ; adiponectin ; CHF ; bmi ; FM
MI ; yielded hazard ratios ; early-onset HF
carvedilol ; von wilebrand factor ; metoprolol ; Î²-adrenergic receptor haplotype
incubation of EC ; HDl ;NYha-IIIb ; phosphorylation ; eNOS-Ser ; phosphorylation ; eNOS-Thr ; HDl
early-onset ; late-onset HF ; HF ; EF ; HF ; change ; HF ; MI
ctnt ; NT-probNP ; aRIC HF model ; aucs ; NRIs
cardiovascular events ; baseline sst2 status ; BB dose ; metoprolol succinate
Medicare ; patients ; acute care hospital ;HF ; AMI ; pna
cochrane effective practice ; organisation of care taxonomy
mouse heart failure ;HF ; hypertensive heart disease ; hh ; pathophysiology ; hh
coPD ; CHF ; cRF ; icc ; kappa coefficients
left ventricular longitudinal systolic strain ; ghs ; left ventricular mechanics ; adverse cardiovascular ;CV ; events ; atrial fibrillation ;AF
implantable cardioverter-defibrillator deactivation preferences ; distressing implantable cardioverter-defibrillator shocks
heart failure ; myocardial function ; dilated poorly contracting ventricles
implantable cardioverter-defibrillator deactivation ; implant ; change ; clinical status ; end-of-life treatment preferences
stable heart failure ; left ventricular ejection fraction ; aerobic training ; dynamic resistance training ; lower limbs
mouse Rad Q65p ; murine equivalent ; human Rad Q66p ; l-type currents ; cav1.2 ; cav1.3 ; wild-type Rad
cRT ; hazard ratio ; confidence interval
fit ; unfit ; cRF distribution ; hazard ratios ; unfit ; overweight ; body mass index ; obese
left ventricular ejection fraction ; egFR
cost ; rhythm-control ; rate-control
preferences ; prescribing ; guideline-recommended medications ; medical records
ethically ; pediatrics ; families ; religious beliefs ; life-sustaining treatment ; legal majority ; decisions
Medicare Patient Safety monitoring system ; mSMS ; adverse event rates ; acute myocardial infarction ; congestive heart failure ; pneumonia ; conditions ; surgery
sarcoplasmic reticular ;SR ; protein ; SR ; pump ; phospholamban ; infarcted hearts ; reversible ; metoprolol
HFPSI model ; blood urea nitrogen ; b-type natriuretic peptide ; New York Heart association ; diabetes ; atrial fibrillation ;flutter
timed up and go ; tg ; tests ; chronic obstructive pulmonary disease ; coPD ; chronic heart failure ;CHf ; chronic renal failure ;CRf
RM ; home telemonitoring ; implanted monitoring devices ; medical ; ss ; contact ; hm
heart failure ;HF ; plasma ; natriuretic peptide ; bem ; ejection fraction ;EF ; HF ; sex differences
gls ; left ventricular ejection fraction ;LVEF ; systolic mitral annulus velocity ; sa ; cv events
HF ; LVEF ; long-term mortality ; LVEF ; LVEF ; long-term mortality
exercise ; intramuscular testosterone supplementation ; chronic heart failure ;CHf ; low testosterone status ; health outcomes
cox regression ; beta-blockers ; beta-blockers ; inappropriate therapy ; antitachycardia pacing ; aTP ; shock therapy
exercise ; Minnesota ; quality of life ; exercise
congestive heart failure ; ED
practice ; angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; Î²-blockers ; heart failure ; ejection fraction
rats ; hearts ; excised ; caspase-3 ; activity ; phosphocreatine ; adenine nucleotides ; cytochrome c ; bcl2 ; Bax ; caspase ; expression
right ventricular pacing ; gene expressions ; Bax ; bcl-2 ; Caspase-3 ; RTq-PCr ; interventricular septum biopsies ; beagle dogs ; heart failure
sodium-restricted dietary ; stop hypertension diet ;DASh ; srd ; left ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling ; hypertensive HFPEF
medication ; physical therapy ; implantable defibrillators ; circulatory support ; transplantation ; heart failure ; therapies
cd34 ; vegFR2 ; cells ; functional capacity ; cd34 ; vegFR2 ; cells ; peak VO2
arginine vasopressin ; aVP ; physiologic ; CHF ; inhibition ; aVP ; vasopressin receptor antagonist therapy ; CHF
practice-level variation ; guideline-recommended treatment ; outpatients ; heart failure ; reduced ejection fraction
aerobic ; resistance training ; exercise capacity ; muscle strength ; cardiac ;NT-ProbNP ; inflammatory ; il6 ; hsCRp
reversibility ; heart failure ; myocardial infarction ;MI ; Î²-adrenoceptor blockade ; infarcted rats ; metoprolol
Resting tension ; fpassive-sarcomere length relations ; muscle strips ; kcl-KI ; unanchors ; titin ; titin ; extracellular matrix ; fpassive
CHF ; anthracycline exposure ; stem cell source ;allogeneic
case-fatality rate ; concurrent HF ; case-fatality rate
hospital ; readmission metrics ; all-cause readmission ; aCR ; potential Preventable Readmission ; pPR ; Centers for Medicare and Medicaid ; 30-day readmission ; cm
metoprolol ; carvedilol ; sympathetic activity ; von Willebrand factor ; arg16 ; gln27 ; gly16 ; lu27
acute HF trials ; RELAX-aHF ; ASTRONAUT ; PRONTO
hospitalized HF ; international classification of Diseases ; Ninth revision ; Clinical modification codes ; principal discharge diagnosis
Pulmonary capillary wedge pressure ; hg ; baseline ; hg ; right atrial pressure ; pulmonary arterial pressure ; pulmonary resistance
Rad Q65p ; gating movement ; wild-type Rad ; Q65p ; l-type channel inhibition ; RGK proteins
SS20 ; heart failure ; proteomics ; actin cytoskeleton pathways ; SS20 ; mitochondrial ; metabolic pathways
aortic insufficiency ;AI ; mechanical circulatory support ; continuous flow ;CF ; left ventricular assist devices ; lVADs ; pulsatile devices
pyridostigmine ; coronary artery ligation ; cardiac vagal ; sympathetic tone ; cardiac remodeling ; left ventricular dysfunction ; HF
follow-up visits
heart failure ; end stage ; refractory ; terminal heart failure
heart failure discharges ; university of connecticut health center
New York Heart association ;NYha ; class II Heart Failure ; eplerenone ; standard Heart Failure Medicines ;EMPHASIS-HF
echocardiograms ; left ventricular base ; midpapillary ; baseline ; IVc occlusion ; biVP ; STE ; twist ; basal rotations ; RS
evidence ; drugs ; RAas ; direct renin inhibitors ; neutral endopeptidase inhibitors ; vasopeptidase inhibitors ; angiotensin receptor blockers
acute heart failure ;HF ; pharmacologic ; therapeutics ; calcium-sensitizing agents ; endothelin ; vasopressin ; adenosine
HF induced ; mice ; phenylephrine ; haemodynamic stress ; surgical method ; transverse aortic constriction ;TAC ; jq1 ; pathological changes ; cardiac hypertrophy
Muscle aerobic capacity ; postexercise phosphocreatine resynthesis ; Fontan
i-miBG ; cardiac washout ; carvedilol ; metoprolol ; Î²-adrenergic receptor haplotype
acute myocardial infarction ;AMI ; incidence of and deaths ; heart failure ;HF ; AMI
h-dKO ; ventricular mass ; cardiac apoptosis ; fibrosis ; Akt ; forkhead box ; o-1 signaling ; impaired cardiac metabolic gene expression ; ATP
bottleneck stent ; anterior descending ; LAD ; proximal circumflex artery ;LCx ; LCx ; LAD
postmarketing trials ; hospitalized heart failure ; hHF ; dipeptidyl peptidase-4 ; dp-4 ; inhibitors ; antihyperglycemic agents
cox modeling ; Heart Failure Patient Severity index ;HFPSI ; university of Michigan ; HF ;um
pde2 overexpression ; cardiomyocytes ; cAMP levels ; l-type ca2 ; inotropic effect ; Î²-AR stimulation ; basal contractility
ATP ; inappropriate shock therapy
Cardiac resynchronization therapy ; cRT ; dialysis-dependent patients ; heart failure ;HF ; cRT ; dialysis
joint associations ; cardiorespiratory fitness ;CRf ; body mass index ; heart failure ;HF ; mortality ; cardiovascular risk factors ; HF ; mortality
eplerenone ; hyperkalemia ; renal function ; EMPHASIS-HF ; eplerenone ; Mild Patients Hospitalization ; SurvIval study ; Heart Failure
Heart rate ;HR ; cardiac patients ; acute myocardial infarction ;AMI ; congestive heart failure ;CHf ; left ventricular ;LV
neonatal rat ; ventricular cardiomyocytes ; chronic insulin exposure ; iRS1 ; irr2 proteins ; insulin action ; p38 ; fundamental mechanism of cardiac dysfunction ; insulin resistance ; type 2 diabetes
echocardiograms ; left ventricular midpapillary ; atrioventricular delay ;AVd ; interventricular delay ;VVd ; STE ; circumferential strain ;CS ; radial strain ;RS
New York Heart association ;NYha ; functional class III HF ; ejection fractions ; chronic stable guideline-directed medical therapy ; ghm ; united states ; europe
non-LBb ; QRs ; hazard ratio ; primary outcome ; QRs ; hazard ratio
dyssynchronous HF ; myofiber shortening velocity ; early-activated septum ; myofiber shortening ; stretch rate ; late-activated lateral wall
label-free shotgun proteomics ; global proteomics ; transverse aortic constriction ;TAC ;-induced heart failure ; signaling pathway
CHF ; c-Kit ; cells ; transforming growth factor-Î² ; tgf-Î² ; epithelial ; mesenchymal transition markers ; expression of pluripotency markers ; shams
pKA ; change ; regulatory ;RIiÎ± ; catalytic ; cÎ± ; expression ; rIIÎ± ; ser96) ; cÎ± ; phosphorylation ; HF
hFrEF ; left ventricular ejection fraction ; HFpEF ; left ventricular ejection fraction ; RAS- ; Î²-blocker dose changes ; index HF
g-protein-coupled receptors ; reciprocal regulation ; mouse hearts ; Î²-adrenergic receptor stimulation ; postischemic heart failure
concentric remodeling ;CR ; concentric hypertrophy ;CH ; left ventricular ;LV ; heart failure ; preserved ejection fraction ;HFpEF ; eccentric hypertrophy ;EH
body ; diet group ; exercise group ; exercise ; diet group
RV dysfunction ;hazard ratio ; cachexia ;hazard ratio
resting HR ; baseline ; VO2max ; resting HR
tg-Î² inhibition ; c-Kit+ cell phenotype ; cardiac progenitor function ; cell expansion protocols
NT-probNP ; inflammatory biomarkers ; hsCRp ; il6) ; hsCRp
BETs ; neurohormonally induced heart disease ; nanomolar doses ; jq1 ; blocked phenylephrine-mediated hypertrophy ; cardiomyocytes ; pathological gene induction
BAT ; exercise capacity ; N-terminal pro-brain natriuretic peptide ; burden of heart failure hospitalizations ; GDm-treated NYHA
p70s6k ; PKc-Î²II ; HDL ;NYha-IIIb ; malondialdehyde bound ; HDL ;NYHA-IIIb ; HDL
MLHF ; exercise ; diet ; exercise ; diet
nonpace ; non-DNx ; sham-innervated ; sham-inv ; nonpace DNx ;sham-nx ; pace non-DNx ;CHf-inv ; pace ; DNx ;CHf-nx
hABC Battery score ; HF ; health ABC ; HF model ; SD ; death
ejection fraction ; frail ; biological phenotype ; risk of death ; frailty ; deficit index
hemoglobin ; ghg ; HRQoL ; training-induced changes ; HRQoL ; Heart Failure ; exercise training ;HF-ACtion
atrial Fibrillation ; congestive Heart Failure trial ; health care expenditures ; QuÃ©bec ; rhythm ; rate-control ; treatment ; cost-minimization
reversible causes ; heart failure ; compliance ; myocardial ischaemia ; tachy- ; bradyarrhythmias ; valvular regurgitation ; pulmonary embolism ; infection ; renal dysfunction
report ; calcineurin ;Nfat signalling ; miR-25 expression ; basic helix-loop-helix ; bhlh ; transcription factor ; dHAND ; hand2 ; mouse ; myocardium
exercise time ; PSs ; btes ; exercise time ; PSs ; btes
NT-probNP cutoff point ; admission ; pg
prognostic power ; r-R interval oscillations ; non-linear HR variability measures ; short-term fractal scaling exponent
diastolic function ; diastolic filling formalism ; relaxation ;viscoelastic ; passive ;stiffness ; doppler mitral inflow velocity ; e-wave
heart failure ;HF ; ventricular tachycardia ;HF ; HF ; VT ;HFVT ; structurally normal hearts ; hNorm
gls ; cox model ; chronic heart failure ; hypertension ; diabetes ; prior stroke score ; glomerular filtration rate ; LVEF ; CV
VAD ; ventricular assist device ; ecmo ; extracorporeal membrane oxygenation membrane ; ecmo ; VAD
ischemic events ;IEs ; ischemic cardiomyopathy ;IC ; cardiac resynchronization therapy ; defibrillator ; cRT-d
cost-effectiveness ; heart failure disease management ; evidence-based treatments ; health care system
resistin ; heart failure ; mouse ; murine resistin ; transgenic ; Retn gene ; hum-retn mice ; basal ; inflammation-stimulated resistin
angiotensin-converting enzyme inhibitors ;angiotensin receptors blockers ; Î²-blockers
TTA ; tgttMena mice ; cardiac injury ; ejection fraction ; heart dilatation ; hypertrophy ; transverse aortic constriction ;TAC
resynchronization-Defibrillation ; Ambulatory Heart Failure Trial ; implantable cardioverter defibrillator-CRT ; primary end point of all-cause mortality ; heart failure
heart failure ; italy ; confirmatory factor analysis ; cf ;SCHf ;Self-Care Maintenance ; self-Care management ; self-Care Confidence
mwt ; NYha ; HFpEF ; hFrEF ; prescribed therapy ; HFpEF ; death ; HF
renal dysfunction ; chronic obstructive pulmonary disease ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction ; iCD shocks ; ischemic cardiomyopathy
Raf-MEK1/2-erk1/2 scaffold proteins ; maladaptive cardiac remodelling
CHF ; testosterone levels ; exercise ; testosterone
MS ; LV dilatation ; treatment for heart failure ;HF ; LV ; MS ; HF ; MR ; prolapse ; degenerative mitral valve
New York Heart association ; kccq ; symptom domains ; Spearman correlations ; HF ; EF ; HFpEF
angiotensin converting enzyme inhibitor ; angiotensin-receptor blockers ; Î²-blockers ; heart failure ; medications
c57b ; ang II infusion ; ang II infusion ; uninephrectomy ; ang II infusion ; salt loading ; ang II infusion ; uninephrectomy ; salt loading ;ANS
early transmitral blood flow velocity ; doppler ; early diastolic mitral annulus velocity ; pulmonary capillary wedge pressure ;PCp ; systolic heart failure ;HF
LV systolic indices ;LV ejection fraction ; LV strain ;strain rate ; systole ; diastolic indices ; LV strain rate ; diastole ; early transmitral flow ; sinus rhythm
peak VO2 ; exercise ; body mass ; diet ; body mass
hazard ratios ; confidence interval ; early-onset HF ; late-onset HF
AMI ; hospital ; hospital ; odds of dying
Mass spectrometry ; circulating NT-probNP ; physiological proteolysis ; pro2-leu3 ; leu3-gly4 ; pro6-gly7 ; pro75-Arg76
ctnt ; NT-probNP ; laboratory report ; ctnt ; NT-probNP ; HF prediction model
HFpEF ; New York Heart association ; mean ejection fraction ; fes
depressed left ventricular ;LV ; systolic pressure ; pressure ; ejection fraction ; cardiac output ; LV ; end-diastolic pressure ; MI ; metoprolol
baroreflex activity Therapy ; Heart Failure ; Redued ejection Fraction ; clinical trial ; carotid ; baroreflex activation therapy ;BAT ; advanced heart failure ;HF
hazard ratio ;HR
la ;HF risk factors ; raised blood glucose levels ; obesity ; tobacco ; aging ; systemic hypertension ;SH ; rheumatic fever ; chagas ; disease ; la
cf ; overweight ; obese body mass index
kccq ; HFpEF ;log ; EF
baseline ; egFR group ; egFR group ; egFR group ; uncontrolled hypertension ; diuretics ; ESRD
myocardial phosphodiesterase-2 ; pde2 ; heart failure ;HF ; pde2 ; beta-adrenergic receptor ;Î²-AR ; cardiomyocytes
heart failure ; cardiac resynchronization therapy ; defibrillator ; implantable cardioverter-defibrillator device ; carvedilol ; ATP ; shock therapy ; metoprolol
ERC ; epicatechin-rich cocoa ; Skm ; mitochondrial structure ;Taub ; Ramirez-sanchez ; ciaraldi ; perkins ; Murphy ; naviaux ; Hogan ; ceballos ; Maisel ; Henry
follow-up ; urgent readmission
Mena overexpression ; TTA ; tgtttMena mice ; TAC ; Mena levels ; cardiac hypertrophy ; TTA ; tgttttMena ; post-TAC ; cardiac
echocardiography ; LV ; end-diastolic volume ; MR ; mitral valve opening ; mVA ; mean pressure gradient ; hg
PD ; diuretic refractory severe-end-stage HF ; PDrelated
ATP production rates ; post-aac ; mitochondrial oxidation ; glucose ; lactate ; fatty acids ; myocardial glycolysis
eplerenone ; potassium ; potassium ; hyperkalemia ; medication
New York Heart association ; heart failure ;HF ; left ventricular ejection fraction ; permanent periodic breathing ;PB ; report
bottleneck stent ; proximal LAD ; LCx ; reversible myocardial ischemia ;open stent ; ischemic heart failure ; stent
potassium ; spironolactone ; non-AAs ; AAs ; race by treatment interaction
obese ; body mass index ; hff
proangiogenic effects ; b ; veGF pathway ; adenoviral vector ; decoy ; veGF receptor ; ad-flk ; adenovirus ; ad-c
surgery ; post-LVAD AI ; aortic valve oversewing ; leaflet repair ; bioprosthetic aortic valve replacement ; CF lVAD ; symptomatic ; AI
exercise-induced pulmonary artery systolic pressure ;PASp ; doppler echocardiography ; right ventricular contractile reserve ; pulmonary hypertension ; right heart failure
MEDline ;EMBAse ; HEalthSTAR ; cinahl ; cochrane Library ; Campbell ; Joanna Briggs institute ; evidence based practice ; reviews and Dissemination ; evidence based practice
health care systems ; systolic heart failure ; Î²-blocker ; angiotensin converting enzyme inhibitor ; angion-receptor blocker
heart failure ; blockade ; neuro-hormonal system ; angiotensin converting enzyme inhibitors ;angiotensin receptor blockers ; angiotensin converting enzyme inhibitors intolerance ; beta receptor blockers ; mineralotic receptor antagonists
open chest model ; twist ; RS ; RS synchrony ; STE ; RVPO ; RS synchrony ; cp ; biVP
tAPse ; PASp ; tAPse-to-PASp ratio ;TApse ;PASp ; cox regression ; Kaplan-meier ; tAPse ; PASp
cPET ; CHF ; exercise ; exercise ; exercise
human heart failure ;HF ; mRNA splicing ; voltage-gated cardiac na+ channel ; sn5a ; truncated ; nonfunctional channels ; trapped ; endoplasmic reticulum
paediatric heart failure ; myocarditis ; dilated cardiomyopathy ; heart failure ; cellular responses ; heart failure ; anthracycline ; childhood malignant disease
economic ; Patient management Interventions ; Heart Failure ; cost-effectiveness model ; evidence-based medications ; costs
natriuretic peptides ;NPs ; b-type NP ; N-terminal pro-B-type NP ; acute heart failure ; Emergency department ;ED ; acute dyspnea
peak oxygen consumption ; peak VO2 ; ven ; vco2 slope ; exercise ; oscillatory ventilation ; eOV ; end-tidal co2 ;PETco2 ; cardiopulmonary exercise testing
denmark ; bisphosphonates ; raloxifene
hypertension ; LV dilatation ; LV dysfunction ; MR ; mitral valve ; closure ; organic lesion ; systolic ; diastolic tethering ; functional etiology ; MR ; MS
tolvaptan ; hyponatremia ; united states ; japan ; congestive heart failure ; diuretic therapy ; serum sodium levels ; systolic function
horizontal longitudinal strain ; left ventricle ; echocardiographic measurements ; baseline echocardiography ; cRT ; follow-up echocardiograms
platelet-activating factor ;PAf ; metabolic enzymes ; heart failure ;HF ; bmi-matched
acute care surgery ; acs ; ot ; transplantation ; medical therapy ;MT ; intravenous inotropes ; ventricular assist devices ;VADs
HFpEF ; ivabradine ; exercise capacity ; left ventricular filling pressure response ; exercise ; peak early diastolic mitral flow velocity ; peak early diastolic mitral annular velocity
renin-angiotensin-aldosterone system ;RAas ; hFrEF ; angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; aldosterone blockade ; HFpEF
lVET ; tonometric indices
heart rate ; blood pressure ; renal function ; spironolactone ; RAS blockers ; Î²-blockers
cardiac performance ; Î²-adrenoceptor blockade ; heart failure ; reversal of changes ; SR ca(2+)-pump function ; reverse cardiac remodeling ; plasma catecholamines
angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers therapy ; Î²-blockers therapy
SS31 ; congestive heart failure phenotypes ; mitochondrial damage induced ; TAC ; mitochondrial proteome changes ; mitochondrial ; nonmitochondrial protein changes
myofibrillar ; ATPase activity ; mRNA levels ; SR ; pump ; phospholamban ; Î±-myosin heavy chain ; mRNA ; Î²-myosin heavy chain ; metoprolol
HDL ;HDl ; CHF-NYHA-III ;HDl ;NYHA-IIIb ; CHF-NYHA-II ;HDl ;NYHA-II
anesthetized dogs ; coronary microembolization-induced HF ; cXL-1020 ; left ventricular end-diastolic pressure ; myocardial oxygen consumption ; ejection fraction ; ventricular power index
md ; md ; relative value ; md ; md
baseline ; heart failure ; administration of contrast agent ; administration
etiologies ; HF ; LA ; idiopathic dilated cardiomyopathy ; c'd ; ischemic ; SH ; valvular ; alcohol
ST2 levels ; functional capacity ; ambulatory patients ; HF ; Heart Failure ; exercise training ;HF-ACtion ; exercise training ; HF
report ; cardiopulmonary exercise testing ; exercise rehabilitation ; chronic heart failure ; exercise rehabilitation ; chronic heart failure ;CHf ; CardioPulmonary exercise testing ; cPET ; exercise rehabilitation ; china
AA ; ischemic HF pathogenesis ; NYHA ; glomerular filtration rate ; heart rate ; hypertension ; diabetes mellitus ; myocardial infarction
HF-action ; exercise training ; HF ; left ventricular ejection fractions ; HRQoL ; Kansas City ; Cardiomyopathy Questionnaire ; kvq ; baseline
cRT ; systolic dysfunction ; resynchronization reVErses remodeling ; Systolic left v entricular dysfunction ; reVERSe ; left ventricular ;LV ; ejection fraction ;LVEF
glomerular filtration rate ; egf ; type 2 diabetes ; total cholesterol ; lDL-cholesterol ; CLnKA GG
echocardiography ; LV ; end-diastolic dimension ; LV ; end-diastolic pressure ;wall stress ; lung weight ; untreated aCF groups ; sham group
e-lateral ; aUC ; s'lateral ; aUC
spironolactone ; hospitalization ; adjusted hazard ratio ; death
cardiac procedures ; driven ; cardioversions ; costs ; antiarrhythmic drugs
diabetes mellitus ; cardiomyopathy origin ; Î²-blocker ; angiotensin-converting enzyme inhibitor ; angiotensin II receptor blocker
eplerenone ; post myocardial infarction ; Heart failure Efficacy ; survival study ;EPheSUS ; post-myocardial infarction ; heart failure ; mortality ; hospitalizations ; aldosterone antagonist eplerenone
carvedilol ; metoprolol ; implantable cardioverter-defibrillator therapy ; MAD-cRT ;Multicenter Automatic Defibrillator Implantation ; Cardiac resynchronization Therapy
heart failure-related mortality ; sudden death
DASh ; srd ; brachial systolic pressure ; central end-systolic pressure ; hg
HF ; obese ; body mass index ; black ethnicity ; idiopathic-dilated cardiomyopathy
mortality ; HF ; LVEF ; Heart Failure Survey ; irrael
left ventricular ejection fraction ; world health organization ; idiopathic dilated cardiomyopathy ; negative coronary angiography
european society of Cardiology ; hff ; heart failure ; LV ejection fraction ; non-dilated left ventricle ; diastolic dysfunction ;impaired LV relaxation ; LV ; diastolic stiffness ; LV filling pressures
signaling paradigms ; Î²1ARs ; s1PR1s ; myocyte ; cAMP production ; report ; receptors ; regulatory ; g-protein-coupled receptor kinase-2
PAf-cpt ; PAf ; lyso-paf-AT ; PAf-AH ; lp-PLA2
heart failure ;mean ejection fraction ; standard cardiac rehabilitation care ; Nordic walking
dRS-stratified hazard ratios ; sitagliptin ; pioglitazone ; sitagliptin ; sulfonylureas ; sitagliptin ; insulin
skeletal muscle mass ; t-score ; sarcopenic range ; muscle wasting ; t-score ; wasting ; t-score
exercise ; testosterone group ; baseline ; peak oxygen uptake ; Beck depression inventory ; leg strength ; medical ; short-Form quality of life ; exercise
RAS ; Î²-blocker uptitrations ; mortality ; HF readmissions ; hFrEF ;hazard ratio ;HR
Heart Failure ; exercise training ;HF-action ; social support ; barriers to exercise ; social support score ;pss ; barriers to exercise score ; btes
ST2 ; hospitalization ;hazard ratio ; cardiovascular death ; HF ; hospitalization ;hazard ratio ; all-cause mortality ;hazard ratio ; hazard ratios ; log2
New York Heart association ; cardiopulmonary exercise testing ; lean mass ; x-ray absorptiometry ; dXA ; calf muscle ; magnetic resonance spectroscopy
low-dose dopamine ; low-dose nesiritide ; diuretic therapy ; renal function ; acute heart failure ; renal dysfunction
cRT ; New York Heart association ; heart failure ; left ventricular ejection fraction ; QRs duration ; echocardiographic evidence ; left ventricular dyssynchrony
left ventricular ;LV ; ejection fraction ; HF ; right-sided cardiac catheterization ; transthoracic echocardiography ; transmitral flow velocities ; mitral annulus velocities ; systole ; diastole
acute coronary syndromes ; CAD ; bNP ; NT-probNP levels ; CAD
baseline ; HF ; activities ; lyso-paf-AT ; PAf-cpt ; PAf ; activities ; PAf-AH ; lp-PLA2
medical therapy ; sternotomy ; aortic valve procedures ; bioprosthetic valve replacement ; dacron patch closure ; aortic valve repairs ; transcatheter aortic valve procedure ; open surgery ; aortic valve replacement
cutoff value ; plasma ; N-terminal pro-b-type natriuretic peptide ;NT-probNP ; acute heart failure ;HF ; emergency department ;ED
cardiac troponin t ; ctnt ; high-sensitivity assay ; N-terminal pro-b-type natriuretic peptide ;NT-probNP ; incident HF ; HF risk prediction ; Atherosclerosis risk in communities ;ARIc
body mass index ; event rate ;HR ; fat mass ; fat-free mass index
interquartile range ; body mass index ;interquartile range ; COPd ; CHF ; cRF
reverse remodeling ; ejection fraction ; mortality ; hospitalizations ; HF ; dialysis
EH ; LV contractility ; LVEF ; ratio of systolic blood pressure ; end-systolic volume ;Î² coefficient ; hg
echocardiography ; LV ; end-diastolic volume index ; LV ejection fraction ; MR ; mitral valve opening ; ms ; mVA ; mean pressure gradient ; fg
clinical trial ; renal optimization strategies evaluation ;ROSe ; acute heart failure ; renal dysfunction ; glomerular filtration rate
bets ; chromatin-mediated signal transduction ; pol II ; co-activating transcription factor networks ; HF pathogenesis ; nuclear factor of activated T cells ; naFAT ; nuclear factor-Îºb ;NF-Îºb ; transcription factor ; gATA4
mortality ; exercise tolerance ; cardiovascular events ; myocardial infarction ; congestive heart failure exacerbation ; arrhythmia ; cardiac death ; hypertension ; venous thrombolic events ; ischemic cerebrovascular events
cardiovascular mortality ; hazard ratio
EO-cFUs ; diabetes ;EO-cFU ; peak VO2 ; diabetes ; EO-cFUs ; peak VO2
immunoblotting ; radioenzymatic ; fluorescence resonance energy transfer-based assays ; video edge detection ; epifluorescence microscopy ; l-type ca2 ; myocardial tissues ; isolated cardiomyocytes ; HF
east ; atrial fibrillation ; Stroke prevention Trial ; onset AF ; stroke ; cha2s2VASc score ; usual care ; early rhythm control therapy ; open ; blinded outcome assessment trial
exercise capacity ; peak oxygen consumption ;VO2 ; QOL ; Minnesota Living with Heart Failure ;MLHF ; heart failure-related QOL
TAC-induced proteomic alterations ; mitochondrial-targeted peptide SS31 ; perturbed mitochondrial function ; upstream signal ; pathway alterations ; TAC ; mitochondrial-targeted peptide drugs ; heart failure
low left ventricular ejection fraction ; HF ; left ventricular ejection fraction ; hospital ; physicians ; acute ; outpatient settings ; medical ; financial costs
HF ;HF ; left ventricular ;LV ; ejection fraction ;HFpEF ; echo-doppler studies ; N-terminal pro-brain-type natriuretic peptide assessment
low-volume EDs ; comorbidities ; hospitalized ; adjusted odds ratio ; high-volume EDs
cardiac transplant ; ECt ; diabetes mellitus ; chronic kidney disease ; glomerular filtration rate
hABC Battery scores ; health ABC ; HF ; risk model ; discrimination ; c-index ; HF
cf ; RMsea ; self-Care management Scale ; cf ; RMsea ; self-Care management scale ; cf ; RMsea ; self-Care ; Confidence scale
BAT ; quality-of-life score ; NYha ; functional class ranking
preoperative hypoalbuminemia ; postoperative normalization ; albumin levels ; hypoalbuminemia ; albumin levels ; lVAD
rehospitalization ; acute myocardial infarction ;AMI ; kidney infection ; urinary tract infection ;UTI
heart failure ;HF ; ischemic ; nonischemic cardiomyopathies ; pharmacological armamentarium ; implantable cardioverter defibrillators ; cardiac resynchronization therapy ; cardiac transplantation ; right ventricular assist devices
SAF ;PF ; central venous pressure ; hg ; sVR index ; dyn ; cardiac index
admission median bNP levels ; EF ; bNP ; EF ; borderline ; pg
heart failure admission ; heart transplantation ;LV assist device ; death ;hazard ratio
LV ejection fraction ; velocity ; circumferential shortening ; systolic elastance ; contractile efficiency ; aCF ; aCF ; allopurinol rats ; o2 ; consumption rate ; isolated cardiomyocytes ; extracellular flux analyzer
HFpEF ; LV ; normal geometry ; LV hypertrophy ;LVh ; relative wall thickness ;RWt ; LVh ; rwt
lCZ696 ; angiotensin receptor ; neprilysin inhibitor ; neprilysin inhibitor prodrug ; angiotensin receptor antagonist valsartan ; hypertension ; heart failure ; preserved ejection fraction ; heart failure ; ejection fraction
blood pressure ; mitral valve plasty ; degenerative MR ; p3 prolapse ; chordal ruptures ; triangular resection ; edge-to-edge anastomosis ; ring annuloplasty ; Physio Ring ; edwards lifesciences ; irvine
shuttle walk test ; peak oxygen uptake ; muscular strength ; echocardiographic measures ; N-terminal pro-brain natriuretic peptide ; inflammatory markers ; depression ; beck depression inventory ; health-related quality of life ;Minnesota Living ; Heart Failure Questionnaire ; medical
term ; LVEF ; long-term mortality ; LVEF ; age-by-LVEF
Wistar-kyoto ; lean ZSF1 ; obese ZSF1 ; obese ZSF1 ; high-fat diet ; metabolic ; renal ; echocardiographic evaluations ; hemodynamically ; euthanization
Kaplan-meier curves ; log-rank testing ; UM/VA ;VA-RT
cox regression ; AF type ; persistent persistent AF ; hypertension ; sinus rhythm ;hazard ratio ;HR
chronic HF-ref ; NYHA ; egf ; potassium ; eplerenone ; hyperkalemia ; wRF
fm ; FM ; body fat distribution ; dual energy x-ray absorptiometry ; dXA ; non-diabetic patients ; chronic heart failure ;CHf ;cc ; non-cachectic CHF ; myocardial infarction-both
baseline ; drug dose ; spironolactone ; end point of death ; hospitalization ; HF ;hazard ratio ; AAs ;hazard ratio
pulmonary arterial hypertension ; chronic thromboembolic pulmonary hypertension ; right ventricular pump ; pulmonary arterial hypertension ; medication ; stress echocardiography ; cardiopulmonary exercise testing
cardiovascular death ; HF hospitalization ; btes ; btes ; cardiovascular death ; HF ; hospitalization ; exercise group ;hazard ratio
CAD ; diabetes ; electrocardiographic ; waves ; left bundle branch block ;odds ratio ; nondiabetes risk factors ; dyslipidemia ; hypertension ; tobacco ;odds ratio
index ED ; low-volume ED cases ; death ;all-cause readmission ; high-volume EDs
implantable cardioverter-defibrillator deactivation ; preferences ; decisions ; implantable cardioverter-defibrillator deactivation
Cardiac magnetic resonance ;hazard ratio ; left atrial area ;hazard ratio ; pulmonary vascular resistance ;hazard ratio ; cardiac events
HF units ; systolic ; left ventricular ejection fraction ; HF ; conditions ; New York Heart association ; echocardiographic ; cardiopulmonary exercise test
end stage heart failure ; ABCd ; american college of Cardiology ; acc ;American Heart association ; AHA ; New York Heart association ;NYHA ; structural heart disease ; heart failure ; physical exertion ; medical
mv ; end-diastolic volume ; LV ; end-systolic volume ; mitral filling flow ; mv ; velocity time ; mitral filling flow ; wave doppler echocardiography ; MR ; mitral valve plasty
statitistical ; RM ; all-cause mortality ; sts HH ; cri ; office hours ; Cri
HFPSI ; Ann arbor Veterans ; affairs ; HF clinic ; hawt ; HFPSI ; va-RT cohort ; VA ; HFPSI
hf ; diuretics ; co-morbidities ; mwt ; NYha
surgery ;HF ; postoperative echocardiography ; LV ; end-diastolic volume index ; LV ejection fraction ; MR ; mitral valve opening ; mitral valve area ; mVA ; mean pressure gradient ; fg
AAs ; non-AAs ; spironolactone dose ; hyperkalemia ;potassium ; hypokalemia ;potassium
LVEF ; long-term mortality ; LVEF ;hazard ratio ; LVEF ; preserved LVEF
HFpEF ; primary outcome ;odds ratio ; NYha ; walk test ; mwt ; adherence ; medications
echo-derived pulmonary arterial systolic pressure ;PASp ; right ventricular ;RV ; tricuspid annular plane systolic excursion ;TAPSe ; diastole ; end-systole ; heart failure ;HF ; cardiac risk
LV reverse remodeling ; pre-CRT ; LV ; end-diastolic ; global longitudinal strain ; left ventricle ; left atrial area ; right ventricular ; end-diastolic area ; right atrial area ; right ventricular fractional area change
receiver operating characteristic curve ; auc ; ratios ; PCp ; confidence interval ; e ;septal ; e-elateral
iRS1 ; irr2 ; heart ; hyperinsulinemia ; myocardial insulin resistance ; cellular dysfunction ; iRS1 ; iRS2 ; heart-specific iRS1 ; irr2 ; double-knockout ; h-dKO ; liver-specific iRS1 ; irr2 ; double-knockout ; l-dKO
b-type natriuretic peptide ; N-terminal pro-B-type natriuretic peptide ; stable coronary artery disease ; bem ; N-terminal fragment ;NT-probNP ; ventricular cardiomyocytes ; ventricular wall stress ; myocardial ischemia
trastuzumab-treated patients ; coronary artery disease ; trastuzumab administration ; CHF
LVEF ; clinical composite response ; cRT on ; cRT OFF ; LV end systolic volume index ; LV mass
tg-Î² signaling ; tg-Î² receptor ; smad ; small-molecule inhibitors ; c-Kit ; cell yield ; epithelial ; mesenchymal transition markers ; pluripotency marker nanog ; c-Kt ; cell differentiation ; cardiomyocyte-like cells
systolic heart failure ;ejection fraction ; placebo ; ivabradine ; SHIft ;Systolic Heart Failure Treatment ; If inhibitor ivabradine Trial ; ivabradine ; echocardiographic
liberal transfusion protocols ; short-term mortality rates ; i2 ; mortality rates ; acute coronary syndrome
risk of death ; unplanned readmission ; physician ; adjusted hazard ratio ;HR
Hazard ratios ; tAPse ;PASp ;hazard ratio ; tAPse ; New York Heart association
hek ; embryonic kidney ; Î²1AR ; s1PR1 ; Î²1AR downregulation ; sphingosine-1-phosphate ; s1PR1 ; downregulation ; isoproterenol ; Î²-adrenergic receptor agonist
baseline ; walk distance ;Kansas City Cardiomyopathy Questionnaire ; Minnesota Living with Heart Failure Questionnaire ; depressive symptoms ; beck depression inventory ; zung self-rated depression scores ; natriuretic peptide ; endothelial function ;flow-mediated dilatation ; left ventricular diastolic function
Renal function ; Chronic Kidney Disease Epidemiology
PARADIGm-HF ; chronic heart failure ; systolic dysfunction ;LV EF ; NYHA II-III ; bNP ; primary endpoint ;cardiovascular death ; hospitalization ; heart failure ; arni ;LCz696 ; sacubiltril ; valsartan
hyperkalemia ; African americans ;AAs ; white ; New York Heart association ;NYHA ; HF ; left ventricular dysfunction ; spironolactone ; aldactone evaluation study ;RALes
Odds ratios ; cardiovascular events ; atrial fibrillation ; left ventricular ejection fraction ; diabetes mellitus ; peripheral vascular disease ; myocardial infarction ; heart failure ; stroke ; glomerular filtration rate ; acute kidney injury
diastolic function ; ea ; ventricular-arterial coupling ; ea
hazard ratios ; disease risk score ; dRS ; saxagliptin ; sitagliptin ; saxagliptin ; pioglitazone ; saxagliptin ; sulfonylureas ; saxagliptin ; insulin
revascularization ;coronary artery bypass surgery ; hazard ratio ; percutaneous coronary intervention ; systolic blood pressure ; left bundle branch block pattern ; baseline electrocardiogram
biomedical treatment ; biomedical treatment ; CHm ; left ventricular ejection fraction ; left ventricular diastolic end diameter
masked outcome assessments ; stable heart failure ; left ventricular ejection fraction ; arg16 ; gln27 ; gly16 ; lu27 haplotype ; Î²2receptor ; equipotent dosages ; carvedilol ; metoprolol
angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; Î²-blockers ; interquartile range
Therapy ; ivabradine ; change ; peak early diastolic mitral flow velocity ; peak early diastolic mitral annular velocity ; exercise capacity ; therapy ; ivabradine ; peak oxygen uptake
PAf ; biosynthetic enzymes ;lyso-paf acetyltransferase ;lyso-paf-AT ; dithiothreitol ; dt ; cdp choline ; 1-alkyl-2-acetyl-sn-glycerol choline ; cholinephosphotransferase ; pf-cp ; catabolic isoenzymes ; pif-acetylhydrolase ;PAf-AH ; lipoprotein-associated phospholipase a2 ; lp-PLA2 ; leukocytes
low-volume ED cases ;hospitalization ;ED ; aOR ; high-volume ED cases ; aOR
ivabradine group ; baseline ; follow-up exercise capacity ; peak oxygen uptake ; exercise-induced ; peak early diastolic mitral flow velocity ; peak early diastolic mitral annular velocity
health Buddy program ; all-cause mortality ;hazard ratio ;HR ; inpatient admissions ; baseline
multivariable-adjusted hazard ratios ; quartiles ; Mediterranean diet score ; DASh ; diet score
ctnt ; NT-probNP ;laboratory report ; aRIC HF ; systolic blood pressure ; antihypertensive medication ; smoking ; diabetes ; body mass index ; coronary heart disease ; heart rate ; HF ; operating characteristic curve ; auc ; discrimination improvement ; net reclassification improvement ; nari
eplerenone ; hyperkalemia ; renal function ; wRF ; EMPHASIS-HF ; heart failure ; reduced ejection fraction ;HF-ref ; New York Heart association ;NYHA ; glomerular filtration rate ; egf ; serum potassium
baseline ; NYha ; change ; quality of life ; Duke activity status index ; Kansas City Cardiomyopathy Questionnaire ; walk test distance
placebo ; low-dose dopamine ; cumulative urine volume ;dopamine
low-dose nesiritide ; cumulative urine volume ;nesiritide
Nordic walking ; functional capacity ; self-reported physical activity ; right grip strength ; depressive symptoms ;Hospital anxiety and depression Scale
hyperkalemia ; wRF ; diabetes ; egf ; systolic blood pressure ; hg ;potassium ; hyperkalemia ; hospitalization ; wRF ; primary outcome ;hospitalization ; HF ; cardiovascular mortality
hazard ratio ; baseline ; glomerular filtration rate ; chronic obstructive pulmonary disease ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction ; iCD shocks ; New York Heart association ; atrial fibrillation ; congestive HF
peak oxygen uptake ; hazard ratio ; confidence interval ; ventilatory efficiency slope ; hemoglobin ; left ventricular ejection fraction ; renal function ; diet ; renal disease ; sodium
Kansas City ; Cardiomyopathy ; Minnesota ; Heart Failure Questionnaire ; Beck depression inventory ; zung ; flow-mediated dilatation diameter ; fes group ; natriuretic peptide ; mitral e/e ; wave ratio
CHF ;Odds Ratio ; pre-HCT ; chest radiation ; hypertension ; genes coding ; NAD(p-oxide subunit RAC2 ; hfe ; doxorubicin efflux transporter ; abc2
